ClinicalTrials.gg
CompletedNCT04801420Updated Sep 15, 2026Results posted

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

A Phase 2 interventional study of VLA15 and Placebo in Lyme Borreliosis, sponsored by Pfizer. Completed at 19 sites in United States. Open to participants aged 5 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
625
Allocation
Randomized
Ages
5 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
7th of 33
625 · median 72
Started
2021
with 6 others
Phase 2
6 of 54
none open now
Registered
33rd of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 7th largest by enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2021, is one of 6 in phase 2, and was the 33rd registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 5 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 50 months per subject.

Read the detailed description

VLA15-221 is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study, which is set up in two parts: Main Study Phase (Part A) and Booster Phase (Part B). In Part A 600 subjects aged 5-65 years will be enrolled 1:1:1 into three groups: Group 1 will be vaccinated with VLA15 at Month 0-2-6, Group 2 will be vaccinated with VLA15 at Month 0-6 and with placebo at Month 2 and Group 3 will be vaccinated with placebo at Month 0-2-6. In Part B all eligible subjects will receive booster injections with VLA15 or placebo at Month 18, 30 and 42.

03

Conditions studied

  • Lyme Borreliosis

Browse trials for

Keywords

  • VLA15
  • Lyme Borreliosis
  • Vaccine
  • Lyme disease
  • Borrelia
04

Who can participate

Ages eligible
5 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is aged 5 to 65 years at the day of screening (Visit 0)
  • Subject is of good general health
  • Parent(s)/legal representative(s) and subject understand the study and its procedures, agree to its provisions

    • for subjects aged 18-65 years: written prior to any study related procedures
    • for subjects aged 5-17 years: written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable, prior to any study related procedures.
  • If subject is of : Subject has a negative serum pregnancy test at screening (Visit 0) and agrees to employ adequate measures according to following timelines:

    • Main Study Phase: duration of entire study
    • Booster Phase: until 5 months after each booster vaccination (Booster 1 until Month 23, Booster 2 until Month 35 and Booster 3 until Month 47)
  • Subject is willing and able to comply with scheduled visits, treatment plan, and other study procedures
  • Subject is available for the duration of the study and can be contacted by telephone during study participation

Exclusion criteria

Exclusion Criteria:

  • Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB, or received treatment for LB within the last 3 months prior to Day 1;
  • Subject received previous vaccination against LB;
  • Subject had a tick bite within 4 weeks prior to Day 1;
  • Subject has a medical history of or currently has a disease;
  • Subject has a medical history of or currently has a neuro- inflammatory or disease;
  • Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in the 3 weeks prior to Day 1;
  • Subject has received an active or passive immunization within 4 weeks prior to Day 1;
  • Subject has received any other registered or non-registered medicinal product in another clinical trial within 4 weeks prior to vaccination at Day 1;
  • Subject has a known or suspected defect of the immune system or received immuno-suppressive therapy within 4 weeks prior to Day 1;
  • Subject has a history of anaphylaxis of unknown cause or severe allergic reactions of unknown cause or has a known or allergic reactions to one of the components of the vaccine;
  • Subject had any in the past 5 years;
  • Subject is pregnant, has plans to become pregnant during the course of the study or is lactating at the time of enrollment;
  • Subject has donated or plans to donate blood or blood-derived products 4 weeks prior to Day 1;
  • Subject has any condition that may compromise its well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
  • Subject is in a dependent relationship with the sponsor/investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
625 participants (actual)

Study arms

  • Experimental
    Part A+B - Group 1

    Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15 at Month 18, 30 and 42

    Biological: VLA15

  • Experimental
    Part A+B - Group 2

    Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15 at Month 18, 30 and 42

    Biological: VLA15 · Biological: Placebo

  • Placebo comparator
    Part A+B - Group 3

    Part A: Placebo at Month 0, 2 and 6 Part B: Placebo at Month 18, 30 and 42

    Biological: Placebo

Interventions

  • BiologicalVLA15

    a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

  • BiologicalPlacebo

    PBS (Phosphate Buffered Saline)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness meeting grading scale (MGS), swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after vaccination 1 at Month 0

  2. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after vaccination 2 at Month 2

  3. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after vaccination 3 at Month 6

  4. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study Phase

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after any vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively

  5. Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study Phase

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay at Day 208 was presented in this outcome measure.

    Time frame: At Day 208 (Month 7)

Secondary outcomes

  1. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 1 Booster Dose

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after vaccination 1 booster dose at Month 18

  2. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2 Booster Dose

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after vaccination 2 booster dose at Month 30

  3. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3 Booster Dose

    Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

    Time frame: From Day 1 to Day 7 after vaccination 3 booster dose at Month 42

  4. Percentage of Participants With Serious Adverse Events (SAEs)

    A SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition.

    Time frame: From Day 1 of vaccination 1 up to 6 months following the last booster dose (up to Month 48)

  5. Percentage of Participants With Adverse Events of Special Interest (AESIs)

    An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor were appropriate.

    Time frame: From Day 1 of vaccination 1 up to 6 months following the last booster dose (up to Month 48)

  6. Percentage of Participants With Unsolicited AE

    An AE was any untoward medical occurrence in a participant administered an investigational product, whether or not related to this treatment. Unsolicited AEs were defined as any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.

    Time frame: Up to 28 Days after vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively, and up to 28 Days after vaccination 1, 2 or 3 booster dose at Month 18, 30 and 42, respectively

  7. Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group

    Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs stratified by age group 5-11, 12-17 and 18-65 years were reported. SAE: any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition. AESI: scientific and medical concern specific to the sponsor's product or program. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AEs: any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.

    Time frame: SAEs & AESIs: From Day 1 of vaccination up to Month 48; Solicited AEs: from Day 1 to Day 7 after vaccination 1, 2, 3, 4, 5 and 6; Unsolicited AEs: up to 28 Days after vaccination 1, 2, 3, 4, 5 and 6

  8. GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Baseline, Days 85, 180, 365 and Month 18

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.

    Time frame: Baseline; Days 85, 180 and 365; Month 18

  9. Seroconversion Rate (SCR) at Days 85, 180, 208, 365 and Month 18

    Seroconversion for enzyme linked immunosorbent assay (ELISA) was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a greater than or equal to (\>=) 4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.

    Time frame: Days 85, 180, 208 and 365; Month 18

  10. Geometric Mean of the Fold Rise (GMFR) for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) at Days 85 and 208

    GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, determined by IgG binding assay at Day 85 and Day 208 were evaluated.

    Time frame: Days 85 and 208

  11. GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Baseline, Days 85, 180, 194, 365 and Month 18

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated. Day 194 data was reported for adult participants only as pre-specified in protocol.

    Time frame: Baseline; Days 85, 180, 194 (18 to 65 years only) and 365; Month 18

  12. SCR Stratified by Age Group at Days 85, 180, 194, 208, 365 and Month 18

    Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA. Day 194 data was reported for adult participants only as pre-specified in protocol.

    Time frame: Days 85, 180, 194 (18 to 65 years only), 208 and 365; Month 18

  13. GMFR for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Days 85 and 208

    GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, stratified by age group (5-11, 12-17 and 18-65 years) determined by IgG binding assay at Day 85 and Day 208 were evaluated.

    Time frame: Days 85 and 208

  14. GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.

    Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

  15. SCR at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

    Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.

    Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

  16. GMFR for IgG Against Each OspA Serotype (ST1 to ST6) at Months 19, 31 and 43 During the Booster Phase

    GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.

    Time frame: Months 19, 31 and 43

  17. GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated.

    Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

  18. SCR Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

    Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.

    Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

  19. GMFR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 19, 31 and 43 During the Booster Phase

    GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6), stratified by age group (5-11, 12-17 and 18-65 years) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.

    Time frame: Months 19, 31 and 43

07

Results

Posted Jun 7, 2023
Limitations and caveats
In adverse events "at risk" refers to participants who received actual treatment, regardless of the treatment group to which they were assigned at randomization.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
Started208209208
Completed128118113
Not completed809195
Withdrew: Adverse event114
Withdrew: Withdrawal by subject201718
Withdrew: Physician decision7910
Withdrew: Moved from study area7710
Withdrew: Lost to follow-up262729
Withdrew: Death100
Withdrew: Other182824
Withdrew: Individual stopping criteria reached020

Outcome measures

PrimaryPercentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness meeting grading scale (MGS), swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after vaccination 1 at Month 0
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain61.0 (52.1 to 69.1)52.8 (43.4 to 61.9)12.6 (8.7 to 17.9)60.3 (55.4 to 65.0)44.5 (40.6 to 48.5)
Tenderness80.5 (72.6 to 86.5)80.7 (72.3 to 87.0)19.6 (14.7 to 25.7)81.6 (77.5 to 85.0)61.2 (57.3 to 65.0)
Erythema/Redness MGS10.0 (5.8 to 16.7)10.1 (5.7 to 17.2)2.5 (1.1 to 5.8)13.1 (10.1 to 16.7)9.6 (7.5 to 12.2)
Swelling MGS5.9 (2.9 to 11.6)4.6 (2.0 to 10.3)0.5 (0.1 to 2.8)9.1 (6.7 to 12.4)6.2 (4.6 to 8.5)
Induration/Hardening MGS9.2 (5.2 to 15.8)3.7 (1.4 to 9.1)1.0 (0.3 to 3.6)8.8 (6.4 to 12.0)6.2 (4.6 to 8.5)
Headache27.3 (20.1 to 35.8)23.1 (16.2 to 31.9)19.6 (14.7 to 25.7)23.4 (19.5 to 27.8)22.1 (19.0 to 25.7)
Muscle pain36.4 (28.3 to 45.2)33.0 (24.9 to 42.3)11.1 (7.4 to 16.2)35.6 (31.0 to 40.4)27.5 (24.0 to 31.2)
Joint pain10.7 (6.4 to 17.5)3.7 (1.4 to 9.1)6.0 (3.5 to 10.2)7.8 (5.6 to 10.9)7.2 (5.4 to 9.6)
Nausea2.5 (0.9 to 7.2)4.6 (2.0 to 10.4)6.0 (3.5 to 10.2)5.3 (3.5 to 8.0)5.6 (4.0 to 7.7)
Vomiting0.8 (0.1 to 4.6)0.0 (0.0 to 3.4)1.0 (0.3 to 3.6)0.8 (0.3 to 2.2)0.8 (0.4 to 2.0)
Fatigue20.0 (13.8 to 28.0)15.6 (10.0 to 23.6)16.5 (12.0 to 22.3)19.7 (16.1 to 23.9)18.6 (15.7 to 21.9)
Fever1.8 (0.5 to 6.3)0.0 (0.0 to 3.8)0.5 (0.1 to 3.0)1.1 (0.4 to 2.8)0.9 (0.4 to 2.1)
PrimaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after vaccination 2 at Month 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain55.6 (46.9 to 64.1)4.8 (2.1 to 10.7)8.5 (5.3 to 13.3)31.9 (27.5 to 36.7)24.3 (21.0 to 27.9)
Tenderness81.0 (73.2 to 86.9)9.5 (5.3 to 16.6)14.7 (10.3 to 20.4)47.3 (42.5 to 52.3)36.7 (32.9 to 40.7)
Erythema/Redness MGS16.3 (10.8 to 23.8)0.0 (0.0 to 3.5)1.6 (0.5 to 4.6)7.4 (5.2 to 10.5)5.5 (3.9 to 7.7)
Swelling MGS13.8 (8.8 to 21.0)0.0 (0.0 to 3.5)0.5 (0.1 to 2.9)5.4 (3.6 to 8.1)3.8 (2.5 to 5.7)
Induration/Hardening MGS12.1 (7.5 to 19.0)0.0 (0.0 to 3.5)0.0 (0.0 to 2.0)5.4 (3.5 to 8.1)3.6 (2.4 to 5.5)
Headache20.3 (14.2 to 28.3)10.6 (6.0 to 18.0)12.6 (8.6 to 18.1)15.5 (12.2 to 19.4)14.5 (11.9 to 17.6)
Muscle pain25.8 (18.9 to 34.2)3.8 (1.5 to 9.5)3.7 (1.8 to 7.4)14.1 (11.0 to 17.9)10.7 (8.4 to 13.5)
Joint pain4.9 (2.3 to 10.2)2.9 (1.0 to 8.1)1.6 (0.5 to 4.6)4.6 (3.0 to 7.2)3.6 (2.4 to 5.5)
Nausea4.9 (2.3 to 10.2)1.9 (0.5 to 6.7)5.8 (3.2 to 10.0)3.6 (2.2 to 6.0)4.3 (2.9 to 6.3)
Vomiting0.0 (0.0 to 3.0)1.0 (0.2 to 5.2)0.0 (0.0 to 2.0)1.3 (0.6 to 3.0)0.9 (0.4 to 2.0)
Fatigue13.8 (8.8 to 21.0)8.7 (4.6 to 15.6)12.1 (8.2 to 17.5)11.9 (9.0 to 15.5)12.0 (9.6 to 14.9)
Fever2.5 (0.9 to 7.2)0.0 (0.0 to 3.8)0.0 (0.0 to 2.1)0.8 (0.3 to 2.4)0.5 (0.2 to 1.6)
PrimaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after vaccination 3 at Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain57.5 (48.6 to 66.0)60.0 (50.4 to 68.9)5.6 (3.1 to 10.1)59.2 (54.1 to 64.1)41.7 (37.6 to 45.9)
Tenderness73.6 (65.1 to 80.6)82.1 (73.7 to 88.2)13.0 (8.8 to 18.7)78.2 (73.7 to 82.1)57.0 (52.8 to 61.1)
Erythema/Redness MGS11.7 (7.1 to 18.6)7.5 (3.9 to 14.2)1.1 (0.3 to 4.0)9.6 (7.0 to 13.1)6.8 (5.0 to 9.3)
Swelling MGS8.4 (4.6 to 14.8)11.3 (6.6 to 18.8)0.6 (0.1 to 3.1)9.1 (6.5 to 12.5)6.3 (4.5 to 8.7)
Induration/Hardening MGS8.4 (4.6 to 14.8)6.6 (3.2 to 13.0)0.6 (0.1 to 3.1)8.2 (5.8 to 11.5)5.7 (4.1 to 8.0)
Headache15.4 (10.0 to 23.0)18.9 (12.6 to 27.4)9.0 (5.6 to 14.1)18.5 (14.8 to 22.8)15.4 (12.6 to 18.7)
Muscle pain27.1 (19.9 to 35.8)29.2 (21.4 to 38.5)7.3 (4.3 to 12.2)28.3 (23.9 to 33.1)21.4 (18.2 to 25.1)
Joint pain8.5 (4.7 to 15.0)2.8 (1.0 to 8.0)3.4 (1.6 to 7.2)5.0 (3.2 to 7.7)4.4 (3.0 to 6.5)
Nausea1.7 (0.5 to 6.0)2.9 (1.0 to 8.1)2.3 (0.9 to 5.7)3.0 (1.7 to 5.4)2.8 (1.7 to 4.5)
Vomiting0.9 (0.2 to 4.7)1.9 (0.5 to 6.7)0.0 (0.0 to 2.1)1.1 (0.4 to 2.8)0.7 (0.3 to 1.9)
Fatigue17.9 (12.0 to 25.9)16.0 (10.3 to 24.2)11.8 (7.8 to 17.4)17.1 (13.6 to 21.3)15.4 (12.6 to 18.7)
Fever0.0 (0.0 to 3.3)1.0 (0.2 to 5.4)0.6 (0.1 to 3.2)0.9 (0.3 to 2.5)0.8 (0.3 to 2.0)
PrimaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study Phase

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after any vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study Phase
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain80.5 (74.3 to 85.5)77.0 (70.5 to 82.5)16.8 (12.4 to 22.5)77.0 (72.7 to 80.8)57.0 (53.0 to 60.8)
Tenderness92.6 (88.0 to 95.6)92.5 (87.8 to 95.5)28.4 (22.7 to 34.8)90.6 (87.5 to 93.1)69.9 (66.2 to 73.4)
Erythema/ Redness MGS26.8 (21.0 to 33.6)18.7 (13.8 to 24.9)3.4 (1.6 to 6.8)21.8 (18.1 to 26.0)15.7 (13.0 to 18.7)
Swelling MGS20.5 (15.4 to 26.8)16.6 (11.9 to 22.6)1.4 (0.5 to 4.2)18.0 (14.6 to 22.0)12.5 (10.1 to 15.3)
Induration/ Hardening MGS19.5 (14.5 to 25.7)14.4 (10.1 to 20.2)1.4 (0.5 to 4.2)16.5 (13.3 to 20.4)11.5 (9.2 to 14.3)
Headache38.4 (31.8 to 45.5)36.4 (29.8 to 43.5)28.8 (23.1 to 35.3)37.4 (32.9 to 42.1)34.6 (30.9 to 38.4)
Muscle pain45.8 (38.9 to 52.9)48.1 (41.1 to 55.3)17.8 (13.2 to 23.6)46.8 (42.0 to 51.6)37.1 (33.4 to 41.0)
Joint pain15.3 (10.8 to 21.1)9.6 (6.2 to 14.7)8.2 (5.2 to 12.7)13.2 (10.3 to 16.8)11.5 (9.2 to 14.3)
Nausea8.4 (5.2 to 13.2)11.2 (7.5 to 16.6)9.6 (6.3 to 14.4)9.6 (7.1 to 12.8)9.6 (7.5 to 12.2)
Vomiting3.2 (1.5 to 6.7)3.2 (1.5 to 6.8)1.0 (0.3 to 3.4)2.9 (1.7 to 5.0)2.2 (1.3 to 3.7)
Fatigue33.2 (26.9 to 40.1)29.9 (23.8 to 36.9)28.4 (22.7 to 34.8)31.4 (27.1 to 36.0)30.4 (26.9 to 34.1)
Fever3.2 (1.5 to 6.7)1.6 (0.5 to 4.6)1.0 (0.3 to 3.4)2.4 (1.3 to 4.4)1.9 (1.1 to 3.3)
PrimaryGeometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study Phase

GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay at Day 208 was presented in this outcome measure.

Time frame:
At Day 208 (Month 7)
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study Phase
TitersGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1331.4 (273.5 to 401.5)197.3 (156.2 to 249.3)23.8 (21.6 to 26.2)
ST2653.9 (557.9 to 766.3)460.3 (370.6 to 571.8)21.9 (20.2 to 23.7)
ST3583.2 (494.4 to 688.0)436.2 (344.8 to 551.8)21.9 (20.2 to 23.9)
ST4420.6 (353.2 to 500.9)245.8 (196.1 to 308.2)23.5 (21.3 to 25.9)
ST5442.3 (374.2 to 522.7)239.4 (190.5 to 301.0)22.4 (20.6 to 24.4)
ST6428.5 (358.8 to 511.8)222.0 (177.4 to 277.8)24.3 (22.2 to 26.7)
SecondaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 1 Booster Dose

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after vaccination 1 booster dose at Month 18
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 1 Booster Dose
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain53.7 (44.9 to 62.4)51.9 (42.5 to 61.0)6.0 (3.1 to 11.4)53.6 (47.9 to 59.3)38.7 (34.2 to 43.4)
Tenderness74.6 (66.2 to 81.5)76.4 (67.6 to 83.3)14.9 (9.9 to 21.9)75.7 (70.5 to 80.2)56.7 (52.0 to 61.3)
Erythema/Redness MGS7.6 (4.0 to 13.8)5.5 (2.5 to 11.5)2.2 (0.8 to 6.3)7.9 (5.3 to 11.6)6.1 (4.2 to 8.8)
Swelling MGS8.4 (4.6 to 14.8)6.5 (3.2 to 12.8)1.5 (0.4 to 5.2)8.7 (5.9 to 12.5)6.4 (4.4 to 9.1)
Induration/Hardening MGS5.0 (2.3 to 10.4)4.6 (2.0 to 10.4)1.5 (0.4 to 5.2)6.2 (3.9 to 9.6)4.7 (3.1 to 7.1)
Headache18.8 (12.8 to 26.8)11.9 (7.1 to 19.3)13.2 (8.5 to 20.0)15.3 (11.6 to 19.9)14.6 (11.6 to 18.3)
Muscle pain21.8 (15.4 to 30.1)33.3 (25.2 to 42.7)8.9 (5.2 to 14.9)28.9 (24.0 to 34.3)22.5 (18.8 to 26.7)
Joint pain5.9 (2.9 to 11.7)0.9 (0.2 to 5.1)1.5 (0.4 to 5.2)3.1 (1.7 to 5.9)2.6 (1.5 to 4.6)
Nausea5.1 (2.4 to 10.7)2.8 (1.0 to 7.9)1.5 (0.4 to 5.2)5.6 (3.5 to 8.9)4.3 (2.7 to 6.6)
Vomiting0.8 (0.1 to 4.6)0.9 (0.2 to 5.1)0.0 (0.0 to 2.8)1.0 (0.4 to 3.0)0.7 (0.2 to 2.1)
Fatigue13.6 (8.5 to 20.9)13.9 (8.6 to 21.7)7.4 (4.1 to 13.1)14.6 (11.0 to 19.1)12.3 (9.5 to 15.8)
Fever0.9 (0.2 to 5.0)0.0 (0.0 to 3.5)0.8 (0.1 to 4.2)0.4 (0.1 to 2.1)0.5 (0.1 to 1.8)
SecondaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2 Booster Dose

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after vaccination 2 booster dose at Month 30
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2 Booster Dose
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain62.4 (53.7 to 70.4)52.7 (43.5 to 61.7)6.7 (3.4 to 12.7)57.1 (51.1 to 62.9)41.6 (36.8 to 46.6)
Tenderness76.8 (68.7 to 83.3)74.1 (65.3 to 81.3)11.7 (7.1 to 18.6)76.5 (71.1 to 81.2)56.4 (51.5 to 61.3)
Erythema/Redness MGS17.6 (11.9 to 25.2)7.1 (3.7 to 13.5)1.7 (0.5 to 5.9)12.7 (9.2 to 17.2)9.3 (6.8 to 12.6)
Swelling MGS18.5 (12.7 to 26.3)7.1 (3.7 to 13.5)1.7 (0.5 to 5.9)14.2 (10.5 to 18.9)10.4 (7.7 to 13.8)
Induration/Hardening MGS12.1 (7.5 to 19.0)10.7 (6.2 to 17.8)2.5 (0.9 to 7.2)12.4 (8.9 to 16.8)9.3 (6.8 to 12.6)
Headache17.1 (11.4 to 24.7)15.3 (9.8 to 23.2)14.2 (9.0 to 21.5)17.7 (13.6 to 22.8)16.6 (13.2 to 20.7)
Muscle pain28.5 (21.2 to 37.0)30.6 (22.8 to 39.7)5.8 (2.9 to 11.6)30.2 (25.0 to 36.0)22.6 (18.7 to 27.0)
Joint pain8.9 (5.1 to 15.3)3.6 (1.4 to 8.9)3.3 (1.3 to 8.3)7.5 (4.9 to 11.4)6.2 (4.2 to 9.1)
Nausea3.3 (1.3 to 8.1)6.3 (3.1 to 12.3)4.1 (1.8 to 9.3)4.9 (2.9 to 8.2)4.7 (3.0 to 7.2)
Vomiting0.8 (0.1 to 4.5)0.9 (0.2 to 4.9)0.0 (0.0 to 3.1)1.1 (0.4 to 3.3)0.8 (0.3 to 2.3)
Fatigue19.5 (13.5 to 27.4)21.4 (14.8 to 29.9)6.7 (3.4 to 12.6)20.3 (15.9 to 25.5)16.1 (12.7 to 20.1)
Fever3.3 (1.3 to 8.2)1.8 (0.5 to 6.3)2.5 (0.9 to 7.1)2.3 (1.0 to 4.9)2.3 (1.2 to 4.4)
SecondaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3 Booster Dose

Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.

Time frame:
From Day 1 to Day 7 after vaccination 3 booster dose at Month 42
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3 Booster Dose
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Pain54.4 (45.7 to 62.9)52.7 (43.5 to 61.8)6.4 (3.1 to 12.6)52.7 (46.4 to 58.8)38.3 (33.4 to 43.5)
Tenderness77.8 (69.8 to 84.2)81.3 (73.0 to 87.4)13.6 (8.4 to 21.3)77.8 (72.2 to 82.5)58.1 (52.9 to 63.1)
Erythema/Redness MGS16.9 (11.4 to 24.5)10.1 (5.7 to 17.2)1.8 (0.5 to 6.4)13.6 (9.8 to 18.5)9.9 (7.2 to 13.5)
Swelling MGS20.2 (14.0 to 28.1)11.0 (6.4 to 18.3)2.7 (0.9 to 7.7)15.6 (11.6 to 20.7)11.6 (8.7 to 15.4)
Induration/Hardening MGS13.7 (8.7 to 20.9)11.0 (6.4 to 18.3)1.8 (0.5 to 6.4)11.9 (8.4 to 16.6)8.8 (6.3 to 12.2)
Headache25.2 (18.4 to 33.5)14.5 (9.2 to 22.3)19.6 (13.3 to 28.0)19.8 (15.2 to 25.2)19.7 (15.9 to 24.2)
Muscle pain22.6 (16.1 to 30.7)22.7 (15.9 to 31.4)6.3 (3.1 to 12.3)22.5 (17.7 to 28.2)17.4 (13.8 to 21.7)
Joint pain6.5 (3.3 to 12.3)2.8 (0.9 to 7.8)1.8 (0.5 to 6.3)4.5 (2.6 to 8.0)3.7 (2.2 to 6.2)
Nausea3.3 (1.3 to 8.1)4.6 (2.0 to 10.3)3.6 (1.4 to 8.9)4.1 (2.3 to 7.4)4.0 (2.4 to 6.5)
Vomiting0.0 (0.0 to 3.0)0.9 (0.2 to 5.0)0.9 (0.2 to 4.9)0.4 (0.1 to 2.3)0.6 (0.2 to 2.0)
Fatigue11.4 (6.9 to 18.2)15.6 (10.0 to 23.6)7.1 (3.7 to 13.5)12.8 (9.2 to 17.6)11.0 (8.2 to 14.7)
Fever0.8 (0.1 to 4.6)0.0 (0.0 to 3.5)1.9 (0.5 to 6.7)0.4 (0.1 to 2.4)0.9 (0.3 to 2.6)
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

A SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition.

Time frame:
From Day 1 of vaccination 1 up to 6 months following the last booster dose (up to Month 48)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Percentage of Participants With Serious Adverse Events (SAEs)0.0 (0.0 to 2.9)3.6 (1.4 to 8.8)6.8 (4.1 to 11.1)3.3 (2.0 to 5.5)4.5 (3.1 to 6.4)
SecondaryPercentage of Participants With Adverse Events of Special Interest (AESIs)

An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor were appropriate.

Time frame:
From Day 1 of vaccination 1 up to 6 months following the last booster dose (up to Month 48)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Percentage of Participants With Adverse Events of Special Interest (AESIs)0.8 (0.1 to 4.3)2.7 (0.9 to 7.6)0.5 (0.1 to 2.7)3.3 (2.0 to 5.5)2.4 (1.5 to 3.9)
SecondaryPercentage of Participants With Unsolicited AE

An AE was any untoward medical occurrence in a participant administered an investigational product, whether or not related to this treatment. Unsolicited AEs were defined as any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.

Time frame:
Up to 28 Days after vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively, and up to 28 Days after vaccination 1, 2 or 3 booster dose at Month 18, 30 and 42, respectively
Reported as:
Number · Percentage of participants
Percentage of Participants With Unsolicited AE
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Percentage of Participants With Unsolicited AE29.1 (21.9 to 37.6)36.6 (28.3 to 45.8)35.0 (28.8 to 41.7)30.8 (26.6 to 35.4)32.2 (28.6 to 35.9)
SecondaryPercentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group

Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs stratified by age group 5-11, 12-17 and 18-65 years were reported. SAE: any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition. AESI: scientific and medical concern specific to the sponsor's product or program. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AEs: any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.

Time frame:
SAEs & AESIs: From Day 1 of vaccination up to Month 48; Solicited AEs: from Day 1 to Day 7 after vaccination 1, 2, 3, 4, 5 and 6; Unsolicited AEs: up to 28 Days after vaccination 1, 2, 3, 4, 5 and 6
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
5-11 Years, SAEs0.0 (0.0 to 10.7)4.0 (0.7 to 19.5)3.9 (1.1 to 13.2)2.9 (1.0 to 8.1)3.2 (1.4 to 7.3)
5-11 Years, AESIs0.0 (0.0 to 10.7)8.0 (2.2 to 25.0)0.0 (0.0 to 7.0)2.9 (1.0 to 8.1)1.9 (0.7 to 5.5)
5-11 Years, Solicited AEs93.8 (79.9 to 98.3)96.0 (80.5 to 99.3)76.5 (63.2 to 86.0)94.2 (88.0 to 97.3)88.4 (82.4 to 92.5)
5-11 Years, Unsolicited AEs15.6 (6.9 to 31.8)32.0 (17.2 to 51.6)29.4 (18.7 to 43.0)19.2 (12.8 to 27.8)22.6 (16.7 to 29.8)
12-17 Years, SAEs0.0 (0.0 to 12.1)0.0 (0.0 to 13.8)6.0 (2.1 to 16.2)3.0 (1.0 to 8.5)4.0 (1.8 to 8.5)
12-17 Years, AESIs0.0 (0.0 to 12.1)0.0 (0.0 to 13.8)2.0 (0.4 to 10.5)2.0 (0.6 to 7.0)2.0 (0.7 to 5.7)
12-17 Years, Solicited AEs96.4 (82.3 to 99.4)100 (86.2 to 100)64.0 (50.1 to 75.9)97.0 (91.5 to 99.0)86.0 (79.5 to 90.7)
12-17 Years, Unsolicited AEs35.7 (20.7 to 54.2)20.8 (9.2 to 40.5)30.0 (19.1 to 43.8)25.0 (17.5 to 34.3)26.7 (20.2 to 34.3)
18-65 Years, SAEs0.0 (0.0 to 5.4)4.8 (1.6 to 13.1)8.6 (4.6 to 15.5)3.7 (1.9 to 7.2)5.3 (3.3 to 8.3)
18-65 Years, AESIs1.5 (0.3 to 8.0)1.6 (0.3 to 8.5)0.0 (0.0 to 3.5)4.2 (2.2 to 7.8)2.8 (1.5 to 5.3)
18-65 Years, Solicited AEs98.5 (92.0 to 99.7)100 (94.3 to 100)68.6 (59.2 to 76.7)96.7 (93.4 to 98.4)87.5 (83.4 to 90.7)
18-65 Years, Unsolicited AEs32.8 (22.8 to 44.7)44.4 (32.8 to 56.7)40.0 (31.1 to 49.6)39.1 (32.8 to 45.7)39.4 (34.2 to 44.8)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Baseline, Days 85, 180, 365 and Month 18

GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.

Time frame:
Baseline; Days 85, 180 and 365; Month 18
Reported as:
Geometric mean · Titers
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Baseline, Days 85, 180, 365 and Month 18
TitersGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1: Baseline21.2 (20.3 to 22.1)20.3 (19.9 to 20.7)21.9 (20.7 to 23.2)
ST1: Day 85116.5 (96.4 to 140.8)20.8 (20.1 to 21.5)21.8 (20.5 to 23.3)
ST1: Day 18038.2 (33.6 to 43.4)21.4 (20.5 to 22.3)22.0 (20.8 to 23.2)
ST1: Day 36540.8 (35.3 to 47.1)30.2 (27.1 to 33.6)21.3 (20.3 to 22.4)
ST1: Month 1827.3 (24.2 to 30.7)22.7 (21.3 to 24.2)21.2 (20.2 to 22.3)
ST2: Baseline20.8 (20.0 to 21.6)20.0 (20.0 to 20.0)21.3 (20.4 to 22.3)
ST2: Day 85262.8 (217.6 to 317.3)21.8 (20.6 to 23.1)21.0 (19.9 to 22.1)
ST2: Day 18070.4 (60.4 to 82.1)21.9 (20.8 to 23.1)21.1 (20.3 to 22.1)
ST2: Day 36567.8 (58.2 to 78.9)54.1 (46.8 to 62.7)20.9 (20.1 to 21.7)
ST2: Month 1835.4 (31.1 to 40.2)30.3 (27.2 to 33.8)20.3 (19.9 to 20.9)
ST3: Baseline20.6 (20.0 to 21.3)20.3 (19.9 to 20.7)20.9 (20.2 to 21.7)
ST3: Day 85249.8 (205.1 to 304.2)22.7 (21.5 to 24.1)20.9 (19.8 to 22.2)
ST3: Day 18065.4 (55.8 to 76.6)22.3 (21.2 to 23.6)21.1 (20.4 to 21.8)
ST3: Day 36563.1 (53.8 to 74.0)58.1 (49.8 to 67.8)20.6 (20.0 to 21.1)
ST3: Month 1834.3 (29.8 to 39.4)33.8 (30.1 to 37.9)20.1 (19.9 to 20.3)
ST4: Baseline20.8 (20.0 to 21.6)20.4 (20.0 to 20.9)21.7 (20.6 to 22.8)
ST4: Day 85147.4 (122.6 to 177.3)21.7 (20.7 to 22.7)21.6 (20.3 to 23.0)
ST4: Day 18047.5 (41.7 to 54.1)22.1 (21.1 to 23.2)22.4 (21.1 to 23.7)
ST4: Day 36552.6 (45.5 to 60.8)37.2 (33.1 to 41.9)20.9 (20.0 to 21.8)
ST4: Month 1832.3 (28.5 to 36.7)25.8 (23.7 to 28.1)21.0 (20.1 to 22.0)
ST5: Baseline20.6 (19.8 to 21.4)20.2 (19.9 to 20.6)20.7 (20.1 to 21.4)
ST5: Day 85164.2 (135.7 to 198.8)21.2 (20.3 to 22.0)20.9 (19.9 to 22.1)
ST5: Day 18052.3 (45.5 to 60.1)21.7 (20.7 to 22.7)20.8 (20.2 to 21.5)
ST5: Day 36554.6 (47.0 to 63.5)38.4 (33.9 to 43.5)20.4 (19.9 to 20.9)
ST5: Month 1829.3 (25.9 to 33.1)24.9 (23.0 to 27.0)20.2 (19.9 to 20.5)
ST6: Baseline22.5 (20.9 to 24.2)21.3 (20.4 to 22.2)22.1 (21.0 to 23.2)
ST6: Day 85143.7 (119.2 to 173.1)22.5 (21.2 to 23.9)22.3 (20.9 to 23.9)
ST6: Day 18049.3 (42.8 to 56.8)23.2 (21.9 to 24.7)22.5 (21.4 to 23.7)
ST6: Day 36557.2 (49.2 to 66.6)38.1 (33.8 to 42.9)21.9 (20.9 to 23.1)
ST6: Month 1832.2 (28.1 to 36.9)25.7 (23.5 to 28.0)21.2 (20.4 to 22.1)
SecondarySeroconversion Rate (SCR) at Days 85, 180, 208, 365 and Month 18

Seroconversion for enzyme linked immunosorbent assay (ELISA) was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a greater than or equal to (\>=) 4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.

Time frame:
Days 85, 180, 208 and 365; Month 18
Reported as:
Number · Percentage of participants
Seroconversion Rate (SCR) at Days 85, 180, 208, 365 and Month 18
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1: Day 8575.0 (67.9 to 80.9)2.6 (1.0 to 6.4)1.8 (0.6 to 5.1)
ST1: Day 18040.4 (33.3 to 47.8)5.0 (2.5 to 9.5)2.9 (1.2 to 6.6)
ST1: Day 20892.9 (88.1 to 95.9)83.5 (77.0 to 88.5)6.7 (3.8 to 11.5)
ST1: Day 36543.2 (35.8 to 50.9)28.8 (22.3 to 36.4)0.6 (0.1 to 3.5)
ST1: Month 1816.6 (11.6 to 23.2)9.7 (5.9 to 15.7)0.0 (0.0 to 2.4)
ST2: Day 8589.9 (84.4 to 93.6)6.5 (3.5 to 11.5)0.6 (0.1 to 3.3)
ST2: Day 18066.7 (59.3 to 73.3)7.5 (4.3 to 12.6)1.2 (0.3 to 4.1)
ST2: Day 20897.6 (94.1 to 99.1)94.3 (89.5 to 97.0)2.4 (0.9 to 6.1)
ST2: Day 36564.8 (57.2 to 71.7)59.0 (51.1 to 66.4)1.3 (0.3 to 4.5)
ST2: Month 1836.3 (29.2 to 44.1)31.3 (24.2 to 39.2)0.0 (0.0 to 2.4)
ST3: Day 8590.5 (85.1 to 94.1)11.0 (7.0 to 16.9)0.6 (0.1 to 3.3)
ST3: Day 18063.7 (56.3 to 70.6)8.7 (5.3 to 14.1)4.1 (2.0 to 8.2)
ST3: Day 20898.8 (95.8 to 99.7)91.8 (86.4 to 95.1)4.2 (2.1 to 8.5)
ST3: Day 36563.0 (55.3 to 70.0)61.5 (53.7 to 68.8)0.6 (0.1 to 3.5)
ST3: Month 1831.2 (24.5 to 38.8)40.3 (32.6 to 48.4)0.6 (0.1 to 3.5)
ST4: Day 8583.9 (77.6 to 88.7)5.2 (2.6 to 9.9)2.4 (0.9 to 5.9)
ST4: Day 18055.0 (47.5 to 62.2)8.1 (4.8 to 13.3)6.4 (3.6 to 11.1)
ST4: Day 20895.9 (91.7 to 98.0)88.6 (82.7 to 92.7)6.7 (3.8 to 11.5)
ST4: Day 36557.4 (49.7 to 64.8)42.9 (35.4 to 50.8)1.3 (0.3 to 4.5)
ST4: Month 1831.2 (24.5 to 38.8)19.4 (13.8 to 26.7)1.3 (0.4 to 4.6)
ST5: Day 8582.7 (76.3 to 87.7)4.5 (2.2 to 9.0)2.4 (0.9 to 5.9)
ST5: Day 18057.9 (50.4 to 65.0)5.6 (3.0 to 10.3)4.1 (2.0 to 8.2)
ST5: Day 20897.1 (93.3 to 98.7)86.7 (80.5 to 91.1)6.7 (3.8 to 11.5)
ST5: Day 36557.4 (49.7 to 64.8)43.6 (36.1 to 51.4)1.3 (0.3 to 4.5)
ST5: Month 1823.6 (17.6 to 30.8)17.4 (12.0 to 24.4)1.3 (0.4 to 4.6)
ST6: Day 8579.9 (73.2 to 85.2)4.5 (2.2 to 9.0)2.4 (0.9 to 5.9)
ST6: Day 18050.0 (42.6 to 57.4)8.7 (5.3 to 14.1)5.2 (2.8 to 9.6)
ST6: Day 20895.3 (91.0 to 97.6)85.4 (79.1 to 90.1)8.5 (5.1 to 13.7)
ST6: Day 36557.1 (49.4 to 64.4)41.7 (34.2 to 49.5)3.2 (1.4 to 7.2)
ST6: Month 1822.2 (16.4 to 29.2)16.7 (11.5 to 23.6)2.6 (1.0 to 6.4)
SecondaryGeometric Mean of the Fold Rise (GMFR) for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) at Days 85 and 208

GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, determined by IgG binding assay at Day 85 and Day 208 were evaluated.

Time frame:
Days 85 and 208
Reported as:
Geometric mean · Fold rise
Geometric Mean of the Fold Rise (GMFR) for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) at Days 85 and 208
Fold riseGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1: Day 855.5 (4.5 to 6.6)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST1: Day 20815.5 (12.8 to 18.8)9.7 (7.7 to 12.3)1.1 (1.0 to 1.2)
ST2: Day 8512.5 (10.4 to 15.2)1.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST2: Day 20831.4 (26.6 to 36.9)23.0 (18.5 to 28.6)1.0 (1.0 to 1.1)
ST3: Day 8512.0 (9.8 to 14.6)1.1 (1.1 to 1.2)1.0 (1.0 to 1.0)
ST3: Day 20828.1 (23.8 to 33.2)21.7 (17.1 to 27.4)1.0 (1.0 to 1.1)
ST4: Day 857.0 (5.8 to 8.4)1.1 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST4: Day 20820.0 (16.8 to 23.9)12.0 (9.6 to 15.0)1.1 (1.0 to 1.2)
ST5: Day 857.9 (6.5 to 9.6)1.0 (1.0 to 1.1)1.0 (1.0 to 1.1)
ST5: Day 20821.3 (17.9 to 25.2)11.8 (9.4 to 14.8)1.1 (1.0 to 1.2)
ST6: Day 856.4 (5.3 to 7.7)1.1 (1.0 to 1.1)1.0 (1.0 to 1.1)
ST6: Day 20819.0 (15.9 to 22.8)10.4 (8.3 to 13.0)1.1 (1.0 to 1.2)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Baseline, Days 85, 180, 194, 365 and Month 18

GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated. Day 194 data was reported for adult participants only as pre-specified in protocol.

Time frame:
Baseline; Days 85, 180, 194 (18 to 65 years only) and 365; Month 18
Reported as:
Geometric mean · Titers
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Baseline, Days 85, 180, 194, 365 and Month 18
TitersGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
5-11 Years, ST1: Baseline21.8 (19.7 to 24.0)21.3 (19.4 to 23.4)22.9 (20.1 to 26.2)
5-11 Years, ST1: Day 85269.5 (219.8 to 330.5)22.2 (19.7 to 25.1)23.0 (18.6 to 28.6)
5-11 Years, ST1: Day 18057.6 (44.8 to 74.0)22.3 (19.6 to 25.3)21.4 (19.4 to 23.6)
5-11 Years, ST1: Day 36563.4 (46.7 to 86.1)44.3 (33.5 to 58.6)20.8 (19.2 to 22.5)
5-11 Years, ST1: Month 1830.8 (23.6 to 40.1)23.2 (20.0 to 26.9)20.8 (19.2 to 22.6)
5-11 Years, ST2: Baseline20.6 (19.4 to 22.0)20.0 (20.0 to 20.0)22.9 (20.0 to 26.3)
5-11 Years, ST2: Day 85625.2 (482.4 to 810.3)23.1 (20.0 to 26.6)22.0 (18.1 to 26.7)
5-11 Years, ST2: Day 180151.0 (117.2 to 194.5)21.3 (19.5 to 23.3)20.8 (19.2 to 22.7)
5-11 Years, ST2: Day 365138.9 (107.7 to 179.2)98.0 (73.2 to 131.2)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 1848.7 (36.4 to 65.1)39.5 (30.5 to 51.0)20.0 (20.0 to 20.0)
5-11 Years, ST3: Baseline20.8 (19.7 to 22.1)20.0 (20.0 to 20.0)22.2 (19.7 to 24.9)
5-11 Years, ST3: Day 85649.6 (494.7 to 853.1)24.4 (20.8 to 28.5)23.0 (18.1 to 29.3)
5-11 Years, ST3: Day 180135.9 (100.2 to 184.5)22.0 (20.0 to 24.3)20.0 (20.0 to 20.0)
5-11 Years, ST3: Day 365118.6 (85.0 to 165.5)120.6 (91.1 to 159.6)20.4 (19.6 to 21.4)
5-11 Years, ST3: Month 1850.0 (36.4 to 68.8)50.9 (39.6 to 65.6)20.5 (19.5 to 21.5)
5-11 Years, ST4: Baseline20.5 (19.5 to 21.6)20.0 (20.0 to 20.0)22.1 (19.7 to 24.9)
5-11 Years, ST4: Day 85354.9 (275.2 to 457.7)22.5 (20.0 to 25.2)22.6 (18.4 to 27.8)
5-11 Years, ST4: Day 18084.7 (65.3 to 109.8)21.6 (19.8 to 23.6)21.3 (19.5 to 23.3)
5-11 Years, ST4: Day 36596.1 (71.8 to 128.4)58.0 (46.0 to 73.1)20.5 (19.5 to 21.4)
5-11 Years, ST4: Month 1842.9 (31.3 to 58.8)26.6 (22.5 to 31.3)20.0 (20.0 to 20.0)
5-11 Years, ST5: Baseline20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)21.9 (19.7 to 24.2)
5-11 Years, ST5: Day 85441.2 (339.3 to 573.7)21.6 (19.7 to 23.6)22.8 (18.3 to 28.4)
5-11 Years, ST5: Day 180109.9 (84.1 to 143.6)21.5 (19.3 to 23.9)21.2 (19.5 to 22.9)
5-11 Years, ST5: Day 365116.6 (87.9 to 154.7)55.1 (41.6 to 73.0)20.8 (19.2 to 22.4)
5-11 Years, ST5: Month 1838.1 (28.6 to 50.8)28.1 (23.2 to 34.1)20.0 (20.0 to 20.0)
5-11 Years, ST6: Baseline26.2 (20.6 to 33.4)20.9 (19.7 to 22.2)23.8 (20.7 to 27.3)
5-11 Years, ST6: Day 85380.4 (293.3 to 493.5)22.6 (20.1 to 25.4)24.2 (19.0 to 30.9)
5-11 Years, ST6: Day 18096.6 (71.4 to 130.6)24.1 (21.1 to 27.5)23.0 (20.3 to 26.0)
5-11 Years, ST6: Day 365113.1 (84.7 to 151.1)64.0 (50.3 to 81.4)22.0 (19.6 to 24.7)
5-11 Years, ST6: Month 1844.2 (31.1 to 62.8)28.8 (23.6 to 35.2)20.5 (19.5 to 21.6)
12-17 Years, ST1: Baseline20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)21.0 (19.6 to 22.6)
12-17 Years, ST1: Day 85198.4 (136.9 to 287.7)20.8 (19.7 to 21.9)20.6 (19.4 to 21.9)
12-17 Years, ST1: Day 18048.3 (36.8 to 63.5)22.6 (20.3 to 25.2)21.9 (20.0 to 24.1)
12-17 Years, ST1: Day 36543.9 (31.8 to 60.5)36.5 (28.7 to 46.4)20.6 (19.4 to 22.0)
12-17 Years, ST1: Month 1831.0 (22.8 to 42.1)24.6 (20.9 to 28.9)20.6 (19.4 to 22.0)
12-17 Years, ST2: Baseline20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
12-17 Years, ST2: Day 85414.3 (284.2 to 604.1)23.7 (19.9 to 28.2)20.0 (20.0 to 20.0)
12-17 Years, ST2: Day 180102.3 (74.0 to 141.4)24.6 (21.0 to 28.9)21.2 (19.5 to 22.9)
12-17 Years, ST2: Day 36568.6 (47.9 to 98.2)72.8 (53.6 to 98.8)20.7 (19.3 to 22.2)
12-17 Years, ST2: Month 1839.8 (28.2 to 56.2)39.3 (30.4 to 50.9)20.0 (20.0 to 20.0)
12-17 Years, ST3: Baseline20.0 (20.0 to 20.0)20.5 (19.5 to 21.5)20.4 (19.6 to 21.2)
12-17 Years, ST3: Day 85426.3 (288.0 to 631.2)24.8 (21.5 to 28.6)20.0 (20.0 to 20.0)
12-17 Years, ST3: Day 180104.5 (75.8 to 143.9)25.1 (21.5 to 29.4)21.5 (19.8 to 23.5)
12-17 Years, ST3: Day 36573.2 (50.8 to 105.5)86.1 (63.4 to 116.8)20.7 (19.3 to 22.3)
12-17 Years, ST3: Month 1841.5 (28.3 to 61.0)44.8 (34.4 to 58.3)20.0 (20.0 to 20.0)
12-17 Years, ST4: Baseline20.0 (20.0 to 20.0)21.8 (20.0 to 23.7)21.4 (19.8 to 23.1)
12-17 Years, ST4: Day 85256.6 (181.0 to 363.7)23.7 (20.7 to 27.0)21.1 (19.5 to 22.8)
12-17 Years, ST4: Day 18068.0 (52.3 to 88.5)24.1 (21.3 to 27.2)22.2 (20.0 to 24.7)
12-17 Years, ST4: Day 36558.6 (42.6 to 80.7)52.4 (40.0 to 68.6)20.0 (20.0 to 20.0)
12-17 Years, ST4: Month 1838.0 (27.7 to 52.2)33.6 (26.8 to 42.0)21.0 (19.6 to 22.5)
12-17 Years, ST5: Baseline20.0 (20.0 to 20.0)21.0 (19.6 to 22.6)21.0 (19.6 to 22.5)
12-17 Years, ST5: Day 85273.7 (190.5 to 393.4)22.8 (20.1 to 25.9)21.0 (19.6 to 22.5)
12-17 Years, ST5: Day 18071.7 (53.2 to 96.7)24.2 (21.1 to 27.7)20.6 (19.4 to 21.8)
12-17 Years, ST5: Day 36560.0 (42.6 to 84.4)56.4 (43.1 to 73.8)20.0 (20.0 to 20.0)
12-17 Years, ST5: Month 1835.8 (25.5 to 50.1)29.5 (23.9 to 36.4)20.6 (19.4 to 21.9)
12-17 Years, ST6: Baseline20.9 (19.6 to 22.4)23.6 (20.4 to 27.2)23.2 (20.4 to 26.4)
12-17 Years, ST6: Day 85229.4 (157.8 to 333.4)26.3 (21.6 to 31.8)22.8 (20.1 to 26.0)
12-17 Years, ST6: Day 18066.2 (49.0 to 89.4)27.3 (23.0 to 32.5)23.8 (20.9 to 27.0)
12-17 Years, ST6: Day 36566.5 (47.4 to 93.2)51.2 (39.4 to 66.5)21.7 (19.7 to 23.8)
12-17 Years, ST6: Month 1837.5 (26.8 to 52.3)31.9 (25.2 to 40.5)22.3 (20.1 to 24.9)
18-65 Years, ST1: Baseline21.4 (20.0 to 23.0)20.0 (20.0 to 20.0)21.9 (20.1 to 23.8)
18-65 Years, ST1: Day 8566.4 (51.8 to 85.1)20.3 (19.7 to 20.8)21.9 (20.2 to 23.7)
18-65 Years, ST1: Day 18029.4 (25.0 to 34.6)20.4 (19.8 to 21.1)22.3 (20.5 to 24.2)
18-65 Years, ST1: Day 194360.8 (238.2 to 546.6)91.6 (60.0 to 139.6)20.8 (19.7 to 22.0)
18-65 Years, ST1: Day 36533.4 (27.8 to 40.0)23.1 (21.0 to 25.4)21.8 (20.1 to 23.6)
18-65 Years, ST1: Month 1824.6 (21.2 to 28.4)21.6 (20.2 to 23.2)21.6 (19.9 to 23.4)
18-65 Years, ST2: Baseline21.2 (19.8 to 22.7)20.0 (20.0 to 20.0)21.3 (20.0 to 22.7)
18-65 Years, ST2: Day 85152.4 (120.0 to 193.6)20.4 (19.8 to 21.0)21.0 (19.9 to 22.1)
18-65 Years, ST2: Day 18044.5 (37.3 to 53.1)21.0 (19.8 to 22.1)21.3 (20.0 to 22.6)
18-65 Years, ST2: Day 194691.5 (519.0 to 921.3)216.7 (143.9 to 326.2)21.0 (19.5 to 22.7)
18-65 Years, ST2: Day 36550.9 (42.3 to 61.4)35.9 (30.6 to 42.3)21.3 (20.0 to 22.8)
18-65 Years, ST2: Month 1829.5 (25.6 to 34.0)23.5 (21.4 to 25.9)20.6 (19.7 to 21.6)
18-65 Years, ST3: Baseline20.8 (19.7 to 22.0)20.3 (19.7 to 20.9)20.7 (19.9 to 21.5)
18-65 Years, ST3: Day 85135.2 (106.4 to 171.9)21.2 (20.1 to 22.3)20.5 (19.8 to 21.3)
18-65 Years, ST3: Day 18040.2 (33.8 to 47.9)21.2 (20.0 to 22.6)21.3 (20.3 to 22.4)
18-65 Years, ST3: Day 194589.2 (428.7 to 809.9)196.6 (129.9 to 297.6)21.2 (19.8 to 22.8)
18-65 Years, ST3: Day 36546.6 (38.6 to 56.3)34.6 (29.4 to 40.6)20.5 (19.8 to 21.3)
18-65 Years, ST3: Month 1827.0 (23.5 to 31.1)24.2 (22.0 to 26.6)20.0 (20.0 to 20.0)
18-65 Years, ST4: Baseline21.3 (19.9 to 22.8)20.0 (20.0 to 20.0)21.6 (20.0 to 23.4)
18-65 Years, ST4: Day 8581.8 (65.3 to 102.6)20.5 (19.8 to 21.1)21.5 (20.0 to 23.2)
18-65 Years, ST4: Day 18032.5 (28.1 to 37.6)21.4 (20.3 to 22.7)22.9 (20.9 to 25.0)
18-65 Years, ST4: Day 194434.4 (306.2 to 616.3)112.4 (75.7 to 166.9)22.5 (19.7 to 25.7)
18-65 Years, ST4: Day 36539.9 (33.5 to 47.6)25.9 (23.1 to 29.0)21.4 (19.9 to 23.2)
18-65 Years, ST4: Month 1826.8 (23.4 to 30.8)22.3 (20.5 to 24.3)21.5 (19.9 to 23.3)
18-65 Years, ST5: Baseline21.1 (19.7 to 22.6)20.0 (20.0 to 20.0)20.2 (19.8 to 20.6)
18-65 Years, ST5: Day 8588.6 (70.4 to 111.4)20.2 (19.8 to 20.6)20.2 (19.8 to 20.7)
18-65 Years, ST5: Day 18034.1 (29.5 to 39.5)20.6 (19.8 to 21.5)20.8 (20.0 to 21.7)
18-65 Years, ST5: Day 194450.5 (328.9 to 617.2)117.1 (78.1 to 175.7)21.1 (19.9 to 22.4)
18-65 Years, ST5: Day 36539.2 (32.9 to 46.7)27.2 (24.0 to 30.7)20.4 (19.8 to 21.1)
18-65 Years, ST5: Month 1824.2 (21.4 to 27.4)21.7 (20.3 to 23.1)20.2 (19.8 to 20.5)
18-65 Years, ST6: Baseline21.7 (20.0 to 23.6)20.5 (19.8 to 21.1)21.0 (20.0 to 21.9)
18-65 Years, ST6: Day 8579.3 (63.5 to 98.9)20.8 (19.9 to 21.9)21.4 (20.3 to 22.6)
18-65 Years, ST6: Day 18033.4 (28.7 to 38.9)21.1 (20.0 to 22.3)21.8 (20.5 to 23.1)
18-65 Years, ST6: Day 194405.5 (289.5 to 568.1)104.8 (70.1 to 156.5)21.7 (20.0 to 23.5)
18-65 Years, ST6: Day 36541.4 (34.5 to 49.7)26.2 (23.4 to 29.2)22.0 (20.5 to 23.6)
18-65 Years, ST6: Month 1826.5 (23.0 to 30.6)21.8 (20.3 to 23.3)21.1 (20.0 to 22.3)
SecondarySCR Stratified by Age Group at Days 85, 180, 194, 208, 365 and Month 18

Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA. Day 194 data was reported for adult participants only as pre-specified in protocol.

Time frame:
Days 85, 180, 194 (18 to 65 years only), 208 and 365; Month 18
Reported as:
Number · Percentage of participants
SCR Stratified by Age Group at Days 85, 180, 194, 208, 365 and Month 18
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
5-11 Years, ST1: Day 8597.4 (86.5 to 99.5)2.9 (0.5 to 14.9)2.6 (0.5 to 13.5)
5-11 Years, ST1: Day 18067.6 (51.5 to 80.4)2.6 (0.5 to 13.5)0.0 (0.0 to 9.0)
5-11 Years, ST1: Day 20897.4 (86.5 to 99.5)97.3 (86.2 to 99.5)2.6 (0.5 to 13.2)
5-11 Years, ST1: Day 36565.7 (49.2 to 79.2)51.4 (35.9 to 66.6)0.0 (0.0 to 9.9)
5-11 Years, ST1: Month 1820.0 (10.0 to 35.9)8.8 (3.0 to 23.0)0.0 (0.0 to 9.4)
5-11 Years, ST2: Day 8597.4 (86.5 to 99.5)11.8 (4.7 to 26.6)2.6 (0.5 to 13.5)
5-11 Years, ST2: Day 18094.6 (82.3 to 98.5)5.3 (1.5 to 17.3)0.0 (0.0 to 9.0)
5-11 Years, ST2: Day 20897.4 (86.5 to 99.5)100 (90.6 to 100)2.6 (0.5 to 13.2)
5-11 Years, ST2: Day 36591.4 (77.6 to 97.0)83.8 (68.9 to 92.3)0.0 (0.0 to 9.9)
5-11 Years, ST2: Month 1857.1 (40.9 to 72.0)50.0 (34.1 to 65.9)0.0 (0.0 to 9.4)
5-11 Years, ST3: Day 8597.4 (86.5 to 99.5)17.6 (8.3 to 33.5)2.6 (0.5 to 13.5)
5-11 Years, ST3: Day 18089.2 (75.3 to 95.7)10.5 (4.2 to 24.1)0.0 (0.0 to 9.0)
5-11 Years, ST3: Day 20897.4 (86.5 to 99.5)100 (90.6 to 100)2.6 (0.5 to 13.2)
5-11 Years, ST3: Day 36580.0 (64.1 to 90.0)91.9 (78.7 to 97.2)0.0 (0.0 to 9.9)
5-11 Years, ST3: Month 1854.3 (38.2 to 69.5)70.6 (53.8 to 83.2)2.7 (0.5 to 13.8)
5-11 Years, ST4: Day 8597.4 (86.5 to 99.5)11.8 (4.7 to 26.6)5.3 (1.5 to 17.3)
5-11 Years, ST4: Day 18089.2 (75.3 to 95.7)7.9 (2.7 to 20.8)5.1 (1.4 to 16.9)
5-11 Years, ST4: Day 20897.4 (86.5 to 99.5)100 (90.6 to 100)5.1 (1.4 to 16.9)
5-11 Years, ST4: Day 36585.7 (70.6 to 93.7)75.7 (59.9 to 86.6)0.0 (0.0 to 9.9)
5-11 Years, ST4: Month 1848.6 (33.0 to 64.4)29.4 (16.8 to 46.2)0.0 (0.0 to 9.4)
5-11 Years, ST5: Day 8597.4 (86.5 to 99.5)8.8 (3.0 to 23.0)5.3 (1.5 to 17.3)
5-11 Years, ST5: Day 18091.9 (78.7 to 97.2)5.3 (1.5 to 17.3)5.1 (1.4 to 16.9)
5-11 Years, ST5: Day 20897.4 (86.5 to 99.5)100 (90.6 to 100)7.7 (2.7 to 20.3)
5-11 Years, ST5: Day 36591.4 (77.6 to 97.0)64.9 (48.8 to 78.2)0.0 (0.0 to 9.9)
5-11 Years, ST5: Month 1842.9 (28.0 to 59.1)29.4 (16.8 to 46.2)0.0 (0.0 to 9.4)
5-11 Years, ST6: Day 8594.9 (83.1 to 98.6)8.8 (3.0 to 23.0)2.6 (0.5 to 13.5)
5-11 Years, ST6: Day 18078.9 (63.7 to 88.9)13.2 (5.8 to 27.3)5.1 (1.4 to 16.9)
5-11 Years, ST6: Day 20894.9 (83.1 to 98.6)100 (90.6 to 100)7.7 (2.7 to 20.3)
5-11 Years, ST6: Day 36583.3 (68.1 to 92.1)73.0 (57.0 to 84.6)0.0 (0.0 to 9.9)
5-11 Years, ST6: Month 1827.8 (15.8 to 44.0)32.4 (19.1 to 49.2)0.0 (0.0 to 9.4)
12-17 Years, ST1: Day 8591.9 (78.7 to 97.2)5.0 (1.4 to 16.5)0.0 (0.0 to 9.0)
12-17 Years, ST1: Day 18059.0 (43.4 to 72.9)12.5 (5.5 to 26.1)7.3 (2.5 to 19.4)
12-17 Years, ST1: Day 20897.4 (86.8 to 99.5)97.5 (87.1 to 99.6)5.3 (1.5 to 17.3)
12-17 Years, ST1: Day 36548.6 (33.0 to 64.4)44.7 (30.1 to 60.3)0.0 (0.0 to 9.6)
12-17 Years, ST1: Month 1827.8 (15.8 to 44.0)16.2 (7.7 to 31.1)0.0 (0.0 to 10.2)
12-17 Years, ST2: Day 8594.6 (82.3 to 98.5)10.0 (4.0 to 23.1)0.0 (0.0 to 9.0)
12-17 Years, ST2: Day 18082.1 (67.3 to 91.0)17.5 (8.7 to 31.9)4.9 (1.3 to 16.1)
12-17 Years, ST2: Day 208100 (91.0 to 100)97.5 (87.1 to 99.6)2.6 (0.5 to 13.5)
12-17 Years, ST2: Day 36565.7 (49.2 to 79.2)71.1 (55.2 to 83.0)2.8 (0.5 to 14.2)
12-17 Years, ST2: Month 1841.7 (27.1 to 57.8)48.6 (33.4 to 64.1)0.0 (0.0 to 10.2)
12-17 Years, ST3: Day 8594.6 (82.3 to 98.5)17.5 (8.7 to 31.9)0.0 (0.0 to 9.0)
12-17 Years, ST3: Day 18084.6 (70.3 to 92.8)17.5 (8.7 to 31.9)7.3 (2.5 to 19.4)
12-17 Years, ST3: Day 208100 (91.0 to 100)97.5 (87.1 to 99.6)7.9 (2.7 to 20.8)
12-17 Years, ST3: Day 36571.4 (54.9 to 83.7)78.9 (63.7 to 88.9)0.0 (0.0 to 9.6)
12-17 Years, ST3: Month 1838.9 (24.8 to 55.1)54.1 (38.4 to 69.0)0.0 (0.0 to 10.2)
12-17 Years, ST4: Day 8597.3 (86.2 to 99.5)5.0 (1.4 to 16.5)0.0 (0.0 to 9.0)
12-17 Years, ST4: Day 18079.5 (64.5 to 89.2)10.0 (4.0 to 23.1)4.9 (1.3 to 16.1)
12-17 Years, ST4: Day 208100 (91.0 to 100)97.5 (87.1 to 99.6)7.9 (2.7 to 20.8)
12-17 Years, ST4: Day 36565.7 (49.2 to 79.2)55.3 (39.7 to 69.9)0.0 (0.0 to 9.6)
12-17 Years, ST4: Month 1844.4 (29.5 to 60.4)29.7 (17.5 to 45.8)0.0 (0.0 to 10.2)
12-17 Years, ST5: Day 8594.6 (82.3 to 98.5)7.5 (2.6 to 19.9)2.6 (0.5 to 13.2)
12-17 Years, ST5: Day 18074.4 (58.9 to 85.4)12.5 (5.5 to 26.1)2.4 (0.4 to 12.6)
12-17 Years, ST5: Day 208100 (91.0 to 100)97.5 (87.1 to 99.6)5.3 (1.5 to 17.3)
12-17 Years, ST5: Day 36565.7 (49.2 to 79.2)63.2 (47.3 to 76.6)0.0 (0.0 to 9.6)
12-17 Years, ST5: Month 1833.3 (20.2 to 49.7)24.3 (13.4 to 40.1)2.9 (0.5 to 14.9)
12-17 Years, ST6: Day 8591.9 (78.7 to 97.2)5.0 (1.4 to 16.5)0.0 (0.0 to 9.0)
12-17 Years, ST6: Day 18066.7 (51.0 to 79.4)15.0 (7.1 to 29.1)7.3 (2.5 to 19.4)
12-17 Years, ST6: Day 208100 (91.0 to 100)95.0 (83.5 to 98.6)10.5 (4.2 to 24.1)
12-17 Years, ST6: Day 36568.6 (52.0 to 81.4)52.6 (37.3 to 67.5)2.8 (0.5 to 14.2)
12-17 Years, ST6: Month 1833.3 (20.2 to 49.7)21.6 (11.4 to 37.2)2.9 (0.5 to 14.9)
18-65 Years, ST1: Day 8559.1 (49.0 to 68.6)1.2 (0.2 to 6.7)2.2 (0.6 to 7.5)
18-65 Years, ST1: Day 18022.1 (14.9 to 31.4)2.4 (0.7 to 8.4)2.2 (0.6 to 7.6)
18-65 Years, ST1: Day 19492.2 (81.5 to 96.9)65.9 (51.1 to 78.1)4.5 (1.3 to 15.1)
18-65 Years, ST1: Day 20889.2 (81.3 to 94.1)70.4 (59.7 to 79.2)9.1 (4.7 to 16.9)
18-65 Years, ST1: Day 36532.6 (23.9 to 42.7)11.1 (6.0 to 19.8)1.1 (0.2 to 6.2)
18-65 Years, ST1: Month 1810.5 (5.6 to 18.7)6.8 (3.0 to 15.1)0.0 (0.0 to 4.3)
18-65 Years, ST2: Day 8584.9 (76.3 to 90.8)2.5 (0.7 to 8.6)0.0 (0.0 to 4.0)
18-65 Years, ST2: Day 18049.5 (39.6 to 59.4)3.6 (1.2 to 10.1)0.0 (0.0 to 4.0)
18-65 Years, ST2: Day 194100 (93.0 to 100)88.6 (76.0 to 95.0)2.3 (0.4 to 11.8)
18-65 Years, ST2: Day 20896.8 (90.9 to 98.9)90.1 (81.7 to 94.9)2.3 (0.6 to 7.9)
18-65 Years, ST2: Day 36554.3 (44.2 to 64.1)42.0 (31.8 to 52.8)1.1 (0.2 to 6.2)
18-65 Years, ST2: Month 1825.6 (17.5 to 35.7)13.7 (7.6 to 23.4)0.0 (0.0 to 4.3)
18-65 Years, ST3: Day 8586.0 (77.5 to 91.6)4.9 (1.9 to 12.0)0.0 (0.0 to 4.0)
18-65 Years, ST3: Day 18045.3 (35.6 to 55.3)3.6 (1.2 to 10.1)4.3 (1.7 to 10.7)
18-65 Years, ST3: Day 194100 (93.0 to 100)86.4 (73.3 to 93.6)4.5 (1.3 to 15.1)
18-65 Years, ST3: Day 20898.9 (94.2 to 99.8)85.2 (75.9 to 91.3)3.4 (1.2 to 9.5)
18-65 Years, ST3: Day 36553.3 (43.1 to 63.1)39.5 (29.6 to 50.4)1.1 (0.2 to 6.2)
18-65 Years, ST3: Month 1818.6 (11.8 to 28.1)19.2 (11.8 to 29.7)0.0 (0.0 to 4.3)
18-65 Years, ST4: Day 8573.1 (63.3 to 81.1)2.5 (0.7 to 8.6)2.2 (0.6 to 7.5)
18-65 Years, ST4: Day 18031.6 (23.1 to 41.5)7.2 (3.4 to 14.9)7.6 (3.7 to 14.9)
18-65 Years, ST4: Day 19498.0 (89.7 to 99.7)77.3 (63.0 to 87.2)6.8 (2.3 to 18.2)
18-65 Years, ST4: Day 20893.5 (86.6 to 97.0)79.0 (68.9 to 86.5)6.8 (3.2 to 14.1)
18-65 Years, ST4: Day 36543.5 (33.8 to 53.7)22.2 (14.5 to 32.4)2.3 (0.6 to 8.0)
18-65 Years, ST4: Month 1818.6 (11.8 to 28.1)9.6 (4.7 to 18.5)2.4 (0.6 to 8.2)
18-65 Years, ST5: Day 8572.0 (62.2 to 80.1)1.2 (0.2 to 6.7)1.1 (0.2 to 5.8)
18-65 Years, ST5: Day 18037.9 (28.8 to 47.9)2.4 (0.7 to 8.4)4.3 (1.7 to 10.7)
18-65 Years, ST5: Day 19498.0 (89.7 to 99.7)77.3 (63.0 to 87.2)4.5 (1.3 to 15.1)
18-65 Years, ST5: Day 20895.7 (89.5 to 98.3)75.3 (64.9 to 83.4)6.8 (3.2 to 14.1)
18-65 Years, ST5: Day 36541.3 (31.8 to 51.5)24.7 (16.6 to 35.1)2.3 (0.6 to 8.0)
18-65 Years, ST5: Month 1811.6 (6.4 to 20.1)8.2 (3.8 to 16.8)1.2 (0.2 to 6.4)
18-65 Years, ST6: Day 8568.8 (58.8 to 77.3)2.5 (0.7 to 8.6)3.2 (1.1 to 9.1)
18-65 Years, ST6: Day 18031.6 (23.1 to 41.5)3.6 (1.2 to 10.1)4.3 (1.7 to 10.7)
18-65 Years, ST6: Day 19498.0 (89.7 to 99.7)77.3 (63.0 to 87.2)6.8 (2.3 to 18.2)
18-65 Years, ST6: Day 20893.5 (86.6 to 97.0)74.1 (63.6 to 82.4)8.0 (3.9 to 15.5)
18-65 Years, ST6: Day 36542.4 (32.8 to 52.6)22.2 (14.5 to 32.4)4.6 (1.8 to 11.2)
18-65 Years, ST6: Month 1815.1 (9.1 to 24.2)6.8 (3.0 to 15.1)3.5 (1.2 to 9.9)
SecondaryGMFR for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Days 85 and 208

GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, stratified by age group (5-11, 12-17 and 18-65 years) determined by IgG binding assay at Day 85 and Day 208 were evaluated.

Time frame:
Days 85 and 208
Reported as:
Geometric mean · Fold rise
GMFR for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Days 85 and 208
Fold riseGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
5-11 Years, ST1: Day 8512.3 (9.8 to 15.3)1.0 (1.0 to 1.1)1.0 (0.8 to 1.2)
5-11 Years, ST1: Day 20832.3 (24.3 to 42.9)25.7 (17.8 to 37.1)1.0 (0.8 to 1.2)
5-11 Years, ST2: Day 8530.2 (23.4 to 39.0)1.2 (1.0 to 1.3)1.0 (0.8 to 1.2)
5-11 Years, ST2: Day 20866.9 (50.5 to 88.6)60.7 (44.9 to 81.9)1.0 (0.8 to 1.2)
5-11 Years, ST3: Day 8530.7 (23.1 to 40.8)1.2 (1.0 to 1.4)1.0 (0.9 to 1.2)
5-11 Years, ST3: Day 20854.7 (40.5 to 74.0)65.1 (47.1 to 89.9)1.0 (0.8 to 1.2)
5-11 Years, ST4: Day 8516.9 (13.0 to 22.1)1.1 (1.0 to 1.3)1.0 (0.8 to 1.2)
5-11 Years, ST4: Day 20843.9 (33.0 to 58.6)33.1 (23.7 to 46.4)1.0 (0.8 to 1.3)
5-11 Years, ST5: Day 8521.7 (16.6 to 28.4)1.1 (1.0 to 1.2)1.0 (0.9 to 1.3)
5-11 Years, ST5: Day 20849.6 (37.3 to 65.9)34.5 (24.9 to 47.7)1.1 (0.9 to 1.3)
5-11 Years, ST6: Day 8514.4 (10.9 to 19.0)1.1 (1.0 to 1.2)1.0 (0.8 to 1.2)
5-11 Years, ST6: Day 20838.8 (26.9 to 56.0)31.5 (22.4 to 44.3)1.1 (0.9 to 1.4)
12-17 Years, ST1: Day 859.9 (6.8 to 14.4)1.0 (1.0 to 1.1)1.0 (0.9 to 1.0)
12-17 Years, ST1: Day 20825.4 (18.1 to 35.7)23.4 (15.7 to 34.8)1.1 (1.0 to 1.2)
12-17 Years, ST2: Day 8520.7 (14.2 to 30.2)1.2 (1.0 to 1.4)1.0 (1.0 to 1.0)
12-17 Years, ST2: Day 20845.2 (34.8 to 58.8)45.3 (31.0 to 66.4)1.0 (1.0 to 1.1)
12-17 Years, ST3: Day 8521.3 (14.4 to 31.6)1.2 (1.1 to 1.4)1.0 (0.9 to 1.0)
12-17 Years, ST3: Day 20843.9 (32.5 to 59.3)46.9 (31.3 to 70.2)1.0 (1.0 to 1.1)
12-17 Years, ST4: Day 8512.8 (9.1 to 18.2)1.1 (1.0 to 1.2)1.0 (0.9 to 1.0)
12-17 Years, ST4: Day 20832.0 (23.8 to 43.0)26.1 (17.7 to 38.4)1.1 (1.0 to 1.2)
12-17 Years, ST5: Day 8513.7 (9.5 to 19.7)1.1 (1.0 to 1.2)1.0 (0.9 to 1.1)
12-17 Years, ST5: Day 20831.7 (24.1 to 41.7)25.8 (17.7 to 37.7)1.0 (0.9 to 1.2)
12-17 Years, ST6: Day 8511.2 (7.8 to 16.2)1.1 (1.0 to 1.2)1.0 (0.9 to 1.0)
12-17 Years, ST6: Day 20830.0 (22.5 to 39.9)19.7 (13.4 to 28.8)1.1 (1.0 to 1.3)
18-65 Years, ST1: Day 853.1 (2.4 to 3.9)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
18-65 Years, ST1: Day 2089.4 (7.2 to 12.2)4.0 (3.1 to 5.3)1.1 (1.0 to 1.3)
18-65 Years, ST2: Day 857.2 (5.7 to 9.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
18-65 Years, ST2: Day 20819.7 (15.9 to 24.4)10.6 (8.1 to 13.7)1.0 (0.9 to 1.1)
18-65 Years, ST3: Day 856.5 (5.1 to 8.2)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
18-65 Years, ST3: Day 20817.7 (14.3 to 22.0)9.0 (6.8 to 11.8)1.1 (1.0 to 1.2)
18-65 Years, ST4: Day 853.8 (3.1 to 4.8)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
18-65 Years, ST4: Day 20811.9 (9.5 to 15.0)5.2 (4.0 to 6.7)1.1 (1.0 to 1.2)
18-65 Years, ST5: Day 854.2 (3.3 to 5.2)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
18-65 Years, ST5: Day 20812.7 (10.3 to 15.8)4.9 (3.8 to 6.4)1.1 (1.0 to 1.2)
18-65 Years, ST6: Day 853.6 (2.9 to 4.5)1.0 (1.0 to 1.1)1.0 (1.0 to 1.1)
18-65 Years, ST6: Day 20811.6 (9.2 to 14.7)4.6 (3.6 to 5.9)1.1 (1.0 to 1.2)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.

Time frame:
Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Reported as:
Geometric mean · Titers
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
TitersGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1: Month 1827.3 (24.2 to 30.7)22.7 (21.3 to 24.2)21.2 (20.2 to 22.3)
ST1: Month 191057.0 (843.1 to 1325.1)830.0 (621.3 to 1108.9)20.9 (20.0 to 21.9)
ST1: Month 23178.2 (142.9 to 222.2)136.9 (107.3 to 174.6)21.4 (20.1 to 22.9)
ST1: Month 2691.0 (74.4 to 111.4)71.1 (56.3 to 89.8)21.9 (20.5 to 23.4)
ST1: Month 3061.1 (49.0 to 76.2)52.6 (42.0 to 65.7)20.3 (19.7 to 20.9)
ST1: Month 311193.1 (967.1 to 1471.8)941.4 (729.8 to 1214.4)21.0 (19.0 to 23.3)
ST1: Month 3997.3 (81.5 to 116.2)89.5 (69.7 to 114.8)21.2 (19.6 to 23.1)
ST1: Month 4278.3 (66.1 to 92.6)68.6 (54.6 to 86.2)20.6 (19.7 to 21.6)
ST1: Month 431044.8 (888.5 to 1228.5)969.8 (768.9 to 1223.2)21.5 (19.1 to 24.2)
ST1: Month 48201.1 (159.9 to 252.8)173.8 (136.8 to 220.9)20.0 (20.0 to 20.0)
ST2: Month 1835.4 (31.1 to 40.2)30.3 (27.2 to 33.8)20.3 (19.9 to 20.9)
ST2: Month 191807.9 (1486.2 to 2199.3)1603.1 (1239.7 to 2073.0)20.5 (19.8 to 21.2)
ST2: Month 23350.5 (294.0 to 417.9)282.6 (228.2 to 349.9)20.9 (19.8 to 22.1)
ST2: Month 26177.1 (148.6 to 211.0)140.6 (112.7 to 175.6)21.5 (20.3 to 22.8)
ST2: Month 30106.9 (85.8 to 133.2)95.2 (76.4 to 118.5)20.3 (19.7 to 20.8)
ST2: Month 311788.6 (1501.0 to 2131.2)1489.7 (1197.1 to 1853.8)21.4 (19.2 to 23.9)
ST2: Month 39172.5 (144.4 to 206.0)150.3 (118.7 to 190.3)20.8 (19.5 to 22.2)
ST2: Month 42132.9 (110.9 to 159.3)115.5 (92.7 to 143.9)20.5 (19.5 to 21.6)
ST2: Month 431622.3 (1407.9 to 1869.4)1555.9 (1253.9 to 1930.7)21.2 (18.9 to 23.9)
ST2: Month 48324.6 (264.4 to 398.5)306.0 (250.4 to 373.8)20.0 (20.0 to 20.0)
ST3: Month 1834.3 (29.8 to 39.4)33.8 (30.1 to 37.9)20.1 (19.9 to 20.3)
ST3: Month 191628.0 (1331.6 to 1990.2)1418.0 (1094.3 to 1837.4)20.8 (20.1 to 21.6)
ST3: Month 23319.5 (261.3 to 390.8)283.6 (225.2 to 357.2)21.0 (19.7 to 22.4)
ST3: Month 26160.9 (133.7 to 193.5)143.9 (114.7 to 180.6)21.6 (20.3 to 23.0)
ST3: Month 3097.9 (77.6 to 123.6)102.6 (82.0 to 128.2)21.2 (20.2 to 22.2)
ST3: Month 311592.0 (1327.3 to 1909.6)1396.0 (1099.7 to 1772.2)21.9 (19.6 to 24.5)
ST3: Month 39155.5 (129.6 to 186.6)151.9 (117.7 to 196.0)21.5 (19.3 to 23.9)
ST3: Month 42118.6 (99.0 to 142.0)119.1 (95.4 to 148.7)20.7 (19.7 to 21.8)
ST3: Month 431388.1 (1192.5 to 1615.9)1393.0 (1104.4 to 1756.9)21.8 (19.3 to 24.5)
ST3: Month 48320.2 (258.0 to 397.5)317.4 (253.5 to 397.4)20.7 (19.7 to 21.8)
ST4: Month 1832.3 (28.5 to 36.7)25.8 (23.7 to 28.1)21.0 (20.1 to 22.0)
ST4: Month 191334.1 (1086.0 to 1639.0)1032.9 (786.1 to 1357.3)21.7 (20.5 to 23.0)
ST4: Month 23227.5 (185.0 to 279.8)170.4 (135.1 to 215.0)22.0 (20.3 to 23.8)
ST4: Month 26122.9 (102.6 to 147.2)90.6 (72.4 to 113.5)22.7 (21.0 to 24.6)
ST4: Month 3081.1 (65.3 to 100.7)63.9 (51.4 to 79.5)21.4 (20.0 to 22.9)
ST4: Month 311493.2 (1242.7 to 1794.2)1123.3 (877.9 to 1437.2)23.2 (20.5 to 26.3)
ST4: Month 39125.1 (104.5 to 149.7)113.6 (89.1 to 144.9)21.9 (19.7 to 24.4)
ST4: Month 42101.8 (85.6 to 121.1)88.0 (70.1 to 110.4)21.9 (20.2 to 23.8)
ST4: Month 431327.6 (1143.7 to 1541.0)1199.4 (964.0 to 1492.3)22.5 (19.8 to 25.6)
ST4: Month 48260.0 (209.3 to 323.0)226.7 (184.2 to 279.1)20.6 (19.5 to 21.7)
ST5: Month 1829.3 (25.9 to 33.1)24.9 (23.0 to 27.0)20.2 (19.9 to 20.5)
ST5: Month 191266.2 (1024.3 to 1565.2)980.1 (745.0 to 1289.4)20.2 (19.8 to 20.7)
ST5: Month 23226.5 (186.1 to 275.7)150.6 (117.6 to 193.0)21.0 (19.8 to 22.2)
ST5: Month 26121.5 (101.1 to 146.1)86.6 (69.2 to 108.4)21.6 (20.3 to 23.0)
ST5: Month 3072.6 (57.8 to 91.2)65.7 (52.8 to 81.7)20.3 (19.7 to 20.9)
ST5: Month 311354.6 (1130.8 to 1622.7)1044.5 (829.9 to 1314.7)22.1 (19.7 to 24.9)
ST5: Month 39119.8 (100.7 to 142.7)106.7 (84.5 to 134.9)21.4 (19.6 to 23.4)
ST5: Month 4291.8 (77.1 to 109.3)83.7 (67.7 to 103.5)20.3 (19.7 to 20.9)
ST5: Month 431195.4 (1030.9 to 1386.3)1097.4 (884.8 to 1361.1)21.5 (19.1 to 24.2)
ST5: Month 48226.0 (181.5 to 281.4)181.2 (141.0 to 232.9)20.3 (19.7 to 21.0)
ST6: Month 1832.2 (28.1 to 36.9)25.7 (23.5 to 28.0)21.2 (20.4 to 22.1)
ST6: Month 191254.9 (1020.7 to 1542.8)957.2 (726.8 to 1260.5)22.3 (21.0 to 23.7)
ST6: Month 23226.3 (184.3 to 277.8)165.7 (131.3 to 209.0)22.2 (20.7 to 23.9)
ST6: Month 26128.0 (106.5 to 153.9)88.6 (70.9 to 110.7)22.6 (21.0 to 24.2)
ST6: Month 3076.3 (60.7 to 95.9)67.3 (54.3 to 83.5)22.1 (20.6 to 23.7)
ST6: Month 311358.1 (1132.7 to 1628.3)1026.8 (813.9 to 1295.3)23.5 (20.7 to 26.7)
ST6: Month 39124.0 (103.4 to 148.8)103.7 (81.8 to 131.4)22.1 (20.0 to 24.5)
ST6: Month 4298.2 (81.8 to 118.0)82.7 (66.2 to 103.5)20.8 (19.7 to 22.0)
ST6: Month 431195.8 (1028.0 to 1391.0)1072.7 (862.9 to 1333.6)22.4 (19.8 to 25.4)
ST6: Month 48240.9 (192.4 to 301.7)203.7 (164.6 to 252.2)21.0 (19.8 to 22.3)
SecondarySCR at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.

Time frame:
Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Reported as:
Number · Percentage of participants
SCR at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1: Month 1816.6 (11.6 to 23.2)9.7 (5.9 to 15.7)0.0 (0.0 to 2.4)
ST1: Month 1996.8 (92.1 to 98.8)94.6 (88.7 to 97.5)0.0 (0.0 to 3.0)
ST1: Month 2387.8 (80.6 to 92.6)80.7 (72.3 to 87.0)1.7 (0.5 to 6.0)
ST1: Month 2675.5 (66.6 to 82.5)62.1 (52.5 to 70.9)3.6 (1.4 to 8.8)
ST1: Month 3057.9 (48.5 to 66.9)49.5 (39.7 to 59.3)0.0 (0.0 to 3.8)
ST1: Month 3197.3 (92.5 to 99.1)98.0 (92.9 to 99.4)1.0 (0.2 to 5.6)
ST1: Month 3980.4 (71.9 to 86.8)71.1 (60.6 to 79.7)2.3 (0.6 to 8.1)
ST1: Month 4277.1 (68.2 to 84.1)67.1 (56.3 to 76.3)2.4 (0.6 to 8.2)
ST1: Month 43100 (96.7 to 100)98.9 (94.0 to 99.8)2.3 (0.6 to 7.9)
ST1: Month 4892.4 (85.1 to 96.3)93.7 (86.0 to 97.3)0.0 (0.0 to 4.9)
ST2: Month 1836.3 (29.2 to 44.1)31.3 (24.2 to 39.2)0.0 (0.0 to 2.4)
ST2: Month 1997.6 (93.2 to 99.2)96.4 (91.1 to 98.6)0.0 (0.0 to 3.0)
ST2: Month 2396.5 (91.4 to 98.6)92.7 (86.2 to 96.2)0.8 (0.1 to 4.6)
ST2: Month 2691.8 (85.2 to 95.6)81.6 (73.0 to 87.9)4.5 (1.9 to 10.0)
ST2: Month 3078.5 (69.8 to 85.2)74.2 (64.7 to 81.9)1.0 (0.2 to 5.6)
ST2: Month 3199.1 (95.2 to 99.8)99.0 (94.4 to 99.8)2.1 (0.6 to 7.2)
ST2: Month 3990.7 (83.6 to 94.8)84.3 (75.0 to 90.6)2.3 (0.6 to 8.1)
ST2: Month 4285.7 (77.8 to 91.1)81.7 (72.0 to 88.6)1.2 (0.2 to 6.4)
ST2: Month 43100 (96.7 to 100)98.9 (94.0 to 99.8)1.1 (0.2 to 6.2)
ST2: Month 4894.6 (87.9 to 97.7)97.5 (91.2 to 99.3)0.0 (0.0 to 4.9)
ST3: Month 1831.2 (24.5 to 38.8)40.3 (32.6 to 48.4)0.6 (0.1 to 3.5)
ST3: Month 1997.6 (93.2 to 99.2)96.4 (91.1 to 98.6)2.4 (0.8 to 6.9)
ST3: Month 2393.0 (86.9 to 96.4)91.7 (85.0 to 95.6)1.7 (0.5 to 6.0)
ST3: Month 2690.0 (83.0 to 94.3)85.4 (77.4 to 91.0)5.4 (2.5 to 11.2)
ST3: Month 3074.8 (65.8 to 82.0)78.4 (69.2 to 85.4)6.2 (2.9 to 12.8)
ST3: Month 3199.1 (95.2 to 99.8)99.0 (94.4 to 99.8)4.1 (1.6 to 10.1)
ST3: Month 3990.7 (83.6 to 94.8)84.3 (75.0 to 90.6)2.3 (0.6 to 8.1)
ST3: Month 4288.6 (81.1 to 93.3)86.6 (77.6 to 92.3)2.4 (0.6 to 8.2)
ST3: Month 43100 (96.7 to 100)98.9 (94.0 to 99.8)3.4 (1.2 to 9.5)
ST3: Month 4895.7 (89.3 to 98.3)96.2 (89.4 to 98.7)2.7 (0.7 to 9.2)
ST4: Month 1831.2 (24.5 to 38.8)19.4 (13.8 to 26.7)1.3 (0.4 to 4.6)
ST4: Month 1997.6 (93.2 to 99.2)94.6 (88.7 to 97.5)3.3 (1.3 to 8.1)
ST4: Month 2391.3 (84.7 to 95.2)88.1 (80.7 to 92.9)2.5 (0.9 to 7.2)
ST4: Month 2686.4 (78.7 to 91.6)72.8 (63.5 to 80.5)7.1 (3.7 to 13.5)
ST4: Month 3072.9 (63.8 to 80.4)60.8 (50.9 to 69.9)1.0 (0.2 to 5.6)
ST4: Month 3199.1 (95.2 to 99.8)98.0 (92.9 to 99.4)3.1 (1.1 to 8.7)
ST4: Month 3985.0 (77.1 to 90.6)80.7 (71.0 to 87.8)2.3 (0.6 to 8.1)
ST4: Month 4282.9 (74.5 to 88.9)74.4 (64.0 to 82.6)4.7 (1.8 to 11.5)
ST4: Month 43100 (96.7 to 100)98.9 (94.0 to 99.8)4.5 (1.8 to 11.1)
ST4: Month 4894.6 (87.9 to 97.7)98.7 (93.2 to 99.8)0.0 (0.0 to 4.9)
ST5: Month 1823.6 (17.6 to 30.8)17.4 (12.0 to 24.4)1.3 (0.4 to 4.6)
ST5: Month 1996.8 (92.1 to 98.8)94.6 (88.7 to 97.5)0.8 (0.1 to 4.5)
ST5: Month 2391.3 (84.7 to 95.2)78.0 (69.3 to 84.7)2.5 (0.9 to 7.2)
ST5: Month 2685.5 (77.7 to 90.8)68.0 (58.4 to 76.2)5.4 (2.5 to 11.2)
ST5: Month 3061.7 (52.2 to 70.3)60.8 (50.9 to 69.9)1.0 (0.2 to 5.6)
ST5: Month 3199.1 (95.2 to 99.8)99.0 (94.4 to 99.8)4.1 (1.6 to 10.1)
ST5: Month 3986.0 (78.2 to 91.3)80.7 (71.0 to 87.8)3.5 (1.2 to 9.8)
ST5: Month 4280.0 (71.4 to 86.5)79.3 (69.3 to 86.6)1.2 (0.2 to 6.4)
ST5: Month 43100 (96.7 to 100)98.9 (94.0 to 99.8)2.3 (0.6 to 7.9)
ST5: Month 4892.4 (85.1 to 96.3)87.3 (78.2 to 93.0)1.3 (0.2 to 7.2)
ST6: Month 1822.2 (16.4 to 29.2)16.7 (11.5 to 23.6)2.6 (1.0 to 6.4)
ST6: Month 1996.9 (92.2 to 98.8)94.6 (88.7 to 97.5)4.1 (1.7 to 9.2)
ST6: Month 2390.4 (83.7 to 94.6)83.5 (75.4 to 89.3)2.5 (0.9 to 7.2)
ST6: Month 2686.4 (78.7 to 91.6)66.0 (56.4 to 74.4)7.1 (3.7 to 13.5)
ST6: Month 3059.8 (50.3 to 68.6)59.8 (49.8 to 69.0)4.1 (1.6 to 10.1)
ST6: Month 3199.1 (95.2 to 99.8)98.0 (92.9 to 99.4)3.1 (1.1 to 8.7)
ST6: Month 3985.0 (77.1 to 90.6)77.1 (67.0 to 84.8)4.7 (1.8 to 11.4)
ST6: Month 4279.0 (70.3 to 85.7)70.7 (60.1 to 79.5)2.4 (0.6 to 8.2)
ST6: Month 43100 (96.7 to 100)98.9 (94.0 to 99.8)3.4 (1.2 to 9.5)
ST6: Month 4892.4 (85.1 to 96.3)93.7 (86.0 to 97.3)1.3 (0.2 to 7.2)
SecondaryGMFR for IgG Against Each OspA Serotype (ST1 to ST6) at Months 19, 31 and 43 During the Booster Phase

GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.

Time frame:
Months 19, 31 and 43
Reported as:
Geometric mean · Fold rise
GMFR for IgG Against Each OspA Serotype (ST1 to ST6) at Months 19, 31 and 43 During the Booster Phase
Fold riseGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
ST1: Month 1938.4 (31.0 to 47.7)36.5 (27.7 to 48.1)1.0 (1.0 to 1.0)
ST1: Month 3119.3 (15.0 to 25.0)19.1 (15.0 to 24.5)1.0 (0.9 to 1.2)
ST1: Month 4313.3 (11.3 to 15.7)14.3 (11.5 to 17.7)1.0 (0.9 to 1.2)
ST2: Month 1950.6 (41.7 to 61.5)53.7 (42.3 to 68.2)1.0 (1.0 to 1.0)
ST2: Month 3116.2 (12.9 to 20.3)15.9 (12.9 to 19.5)1.1 (1.0 to 1.2)
ST2: Month 4312.2 (10.3 to 14.4)13.6 (10.8 to 17.0)1.0 (0.9 to 1.2)
ST3: Month 1946.7 (38.3 to 57.1)44.9 (35.6 to 56.6)1.0 (1.0 to 1.1)
ST3: Month 3116.6 (13.2 to 21.1)14.1 (11.5 to 17.2)1.0 (0.9 to 1.2)
ST3: Month 4311.6 (10.0 to 13.5)11.6 (9.4 to 14.3)1.1 (0.9 to 1.2)
ST4: Month 1940.1 (32.6 to 49.2)40.9 (31.5 to 53.0)1.0 (1.0 to 1.1)
ST4: Month 3118.1 (14.3 to 23.0)18.1 (14.6 to 22.5)1.1 (1.0 to 1.2)
ST4: Month 4313.1 (11.1 to 15.4)13.6 (11.0 to 17.0)1.1 (0.9 to 1.2)
ST5: Month 1941.3 (33.5 to 50.9)40.5 (31.3 to 52.4)1.0 (1.0 to 1.0)
ST5: Month 3118.5 (14.6 to 23.5)16.5 (13.4 to 20.4)1.1 (1.0 to 1.2)
ST5: Month 4313.0 (11.1 to 15.2)13.1 (10.6 to 16.1)1.1 (1.0 to 1.2)
ST6: Month 1937.2 (30.2 to 45.8)37.4 (28.9 to 48.5)1.0 (1.0 to 1.1)
ST6: Month 3118.2 (14.4 to 23.1)15.4 (12.5 to 19.0)1.1 (0.9 to 1.2)
ST6: Month 4312.0 (10.3 to 14.0)13.0 (10.5 to 16.1)1.1 (0.9 to 1.2)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated.

Time frame:
Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Reported as:
Geometric mean · Titers
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
TitersGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
5-11 Years, ST1: Month 1830.8 (23.6 to 40.1)23.2 (20.0 to 26.9)20.8 (19.2 to 22.6)
5-11 Years, ST1: Month 191778.9 (1154.1 to 2742.0)1415.6 (657.0 to 3049.9)20.0 (20.0 to 20.0)
5-11 Years, ST1: Month 23230.2 (151.2 to 350.4)191.4 (112.3 to 326.4)20.0 (20.0 to 20.0)
5-11 Years, ST1: Month 26123.0 (83.8 to 180.4)85.9 (50.1 to 147.2)20.0 (20.0 to 20.0)
5-11 Years, ST1: Month 30115.0 (68.6 to 192.7)61.6 (36.5 to 103.9)20.0 (20.0 to 20.0)
5-11 Years, ST1: Month 311954.0 (1198.9 to 3184.7)1353.1 (669.2 to 2736.0)24.8 (15.9 to 38.5)
5-11 Years, ST1: Month 39119.6 (79.5 to 179.7)200.9 (119.8 to 336.9)23.6 (16.7 to 33.6)
5-11 Years, ST1: Month 42113.8 (79.6 to 162.7)107.3 (67.7 to 170.0)23.5 (18.5 to 29.7)
5-11 Years, ST1: Month 431752.4 (1280.9 to 2397.4)2399.3 (1610.6 to 3574.2)20.0 (20.0 to 20.0)
5-11 Years, ST1: Month 48342.2 (200.1 to 585.1)289.2 (151.4 to 552.7)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 1848.7 (36.4 to 65.1)39.5 (30.5 to 51.0)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 192988.8 (1955.7 to 4567.7)1994.9 (872.8 to 4559.5)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 23455.0 (318.2 to 650.6)354.9 (199.4 to 631.7)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 26273.5 (220.7 to 338.9)168.7 (90.0 to 316.2)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 30215.5 (145.6 to 319.0)118.3 (68.2 to 205.2)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 312802.1 (1724.3 to 4553.5)2151.1 (1095.7 to 4223.3)25.0 (15.7 to 39.6)
5-11 Years, ST2: Month 39217.0 (142.5 to 330.4)280.2 (162.7 to 482.6)22.9 (17.2 to 30.5)
5-11 Years, ST2: Month 42185.8 (124.5 to 277.4)187.7 (120.3 to 292.8)22.8 (17.3 to 30.0)
5-11 Years, ST2: Month 432631.6 (1989.6 to 3480.7)3900.7 (2855.5 to 5328.4)20.0 (20.0 to 20.0)
5-11 Years, ST2: Month 48570.7 (384.9 to 846.1)575.7 (337.1 to 983.2)20.0 (20.0 to 20.0)
5-11 Years, ST3: Month 1850.0 (36.4 to 68.8)50.9 (39.6 to 65.6)20.5 (19.5 to 21.5)
5-11 Years, ST3: Month 192637.1 (1667.7 to 4170.0)2046.5 (927.0 to 4518.1)21.8 (19.7 to 24.1)
5-11 Years, ST3: Month 23416.4 (281.1 to 616.8)417.0 (248.2 to 700.7)20.0 (20.0 to 20.0)
5-11 Years, ST3: Month 26216.1 (147.4 to 316.8)187.6 (107.3 to 327.7)20.6 (19.4 to 21.9)
5-11 Years, ST3: Month 30173.9 (102.0 to 296.4)155.4 (96.4 to 250.5)20.6 (19.3 to 22.1)
5-11 Years, ST3: Month 312496.3 (1509.5 to 4128.2)2158.8 (1109.1 to 4201.9)24.9 (15.8 to 39.0)
5-11 Years, ST3: Month 39178.4 (111.2 to 286.2)372.4 (215.1 to 644.8)24.7 (15.9 to 38.5)
5-11 Years, ST3: Month 42179.7 (117.3 to 275.2)186.8 (121.1 to 288.2)21.6 (18.4 to 25.3)
5-11 Years, ST3: Month 432217.9 (1600.7 to 3073.0)3824.8 (2719.1 to 5380.1)21.8 (19.2 to 24.6)
5-11 Years, ST3: Month 48552.8 (350.8 to 871.1)665.8 (396.9 to 1117.0)22.1 (17.8 to 27.5)
5-11 Years, ST4: Month 1842.9 (31.3 to 58.8)26.6 (22.5 to 31.3)20.0 (20.0 to 20.0)
5-11 Years, ST4: Month 192201.9 (1439.7 to 3367.7)1501.4 (705.0 to 3197.4)21.9 (19.7 to 24.4)
5-11 Years, ST4: Month 23319.4 (221.9 to 459.8)227.8 (137.3 to 378.2)20.0 (20.0 to 20.0)
5-11 Years, ST4: Month 26174.9 (130.3 to 234.8)95.1 (55.5 to 163.0)20.0 (20.0 to 20.0)
5-11 Years, ST4: Month 30148.7 (89.6 to 246.7)80.5 (49.1 to 132.0)21.1 (18.9 to 23.6)
5-11 Years, ST4: Month 312343.1 (1449.4 to 3787.7)1583.6 (780.5 to 3212.9)26.0 (16.7 to 40.5)
5-11 Years, ST4: Month 39147.8 (97.9 to 223.2)215.1 (117.8 to 392.5)24.0 (16.4 to 35.1)
5-11 Years, ST4: Month 42158.6 (114.1 to 220.5)112.3 (63.5 to 198.4)23.5 (18.6 to 29.6)
5-11 Years, ST4: Month 431998.3 (1458.7 to 2737.5)2890.2 (2074.0 to 4027.5)20.0 (20.0 to 20.0)
5-11 Years, ST4: Month 48443.6 (273.2 to 720.3)410.0 (240.3 to 699.5)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 1838.1 (28.6 to 50.8)28.1 (23.2 to 34.1)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 192300.8 (1523.2 to 3475.4)1508.5 (689.1 to 3302.0)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 23323.0 (219.7 to 474.7)217.6 (121.4 to 390.0)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 26197.2 (152.7 to 254.5)111.2 (63.8 to 193.6)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 30147.1 (91.6 to 236.2)90.5 (56.1 to 146.0)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 312203.7 (1378.3 to 3523.3)1503.5 (776.7 to 2910.5)25.1 (15.7 to 40.0)
5-11 Years, ST5: Month 39138.4 (89.1 to 215.1)216.9 (120.3 to 391.3)23.8 (16.5 to 34.3)
5-11 Years, ST5: Month 42144.2 (104.5 to 198.8)114.4 (67.2 to 194.7)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 432019.2 (1494.0 to 2729.1)2548.2 (1845.4 to 3518.6)20.0 (20.0 to 20.0)
5-11 Years, ST5: Month 48391.6 (243.3 to 630.3)293.9 (149.8 to 576.8)20.0 (20.0 to 20.0)
5-11 Years, ST6: Month 1844.2 (31.1 to 62.8)28.8 (23.6 to 35.2)20.5 (19.5 to 21.6)
5-11 Years, ST6: Month 192260.9 (1496.1 to 3416.6)1515.5 (691.7 to 3320.4)22.8 (20.0 to 25.9)
5-11 Years, ST6: Month 23311.2 (210.4 to 460.5)236.5 (129.7 to 431.4)21.6 (19.4 to 24.0)
5-11 Years, ST6: Month 26181.3 (139.3 to 236.1)117.0 (64.7 to 211.5)20.9 (19.1 to 22.8)
5-11 Years, ST6: Month 30137.4 (84.0 to 224.6)100.6 (63.5 to 159.5)20.9 (19.1 to 22.8)
5-11 Years, ST6: Month 312172.0 (1355.4 to 3480.6)1535.5 (773.0 to 3049.8)28.3 (17.7 to 45.3)
5-11 Years, ST6: Month 39153.7 (109.6 to 215.5)219.1 (119.2 to 402.6)23.9 (16.5 to 34.7)
5-11 Years, ST6: Month 42129.0 (89.0 to 186.9)116.4 (65.2 to 207.9)21.6 (18.3 to 25.5)
5-11 Years, ST6: Month 431967.4 (1448.4 to 2672.4)2723.5 (2059.6 to 3601.6)20.9 (19.1 to 22.9)
5-11 Years, ST6: Month 48396.3 (249.0 to 630.9)361.5 (220.5 to 592.5)20.0 (20.0 to 20.0)
12-17 Years, ST1: Month 1831.0 (22.8 to 42.1)24.6 (20.9 to 28.9)20.6 (19.4 to 22.0)
12-17 Years, ST1: Month 191442.0 (899.5 to 2311.5)1958.4 (1111.1 to 3451.7)20.8 (19.1 to 22.7)
12-17 Years, ST1: Month 23288.3 (189.7 to 438.2)220.0 (131.9 to 367.1)21.3 (18.7 to 24.3)
12-17 Years, ST1: Month 26122.1 (77.2 to 193.1)109.8 (61.4 to 196.4)21.4 (18.6 to 24.7)
12-17 Years, ST1: Month 3086.8 (47.9 to 157.4)84.4 (47.2 to 150.9)21.5 (18.4 to 25.1)
12-17 Years, ST1: Month 312125.7 (1487.7 to 3037.3)2040.7 (1326.0 to 3140.8)20.0 (20.0 to 20.0)
12-17 Years, ST1: Month 39135.2 (92.8 to 196.8)143.0 (87.4 to 234.1)20.0 (20.0 to 20.0)
12-17 Years, ST1: Month 42100.2 (69.4 to 144.5)89.2 (53.6 to 148.7)20.0 (20.0 to 20.0)
12-17 Years, ST1: Month 431244.9 (839.2 to 1846.9)1638.9 (1037.2 to 2589.6)21.8 (18.2 to 26.0)
12-17 Years, ST1: Month 48185.1 (109.9 to 311.7)207.4 (120.3 to 357.6)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 1839.8 (28.2 to 56.2)39.3 (30.4 to 50.9)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 191963.1 (1226.3 to 3142.5)3149.2 (1904.3 to 5207.9)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 23468.8 (316.7 to 694.1)412.2 (277.3 to 612.7)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 26241.4 (164.1 to 355.1)278.2 (203.5 to 380.2)21.1 (18.8 to 23.7)
12-17 Years, ST2: Month 30135.3 (73.2 to 250.1)169.7 (113.0 to 254.6)21.4 (18.6 to 24.6)
12-17 Years, ST2: Month 312644.4 (1812.2 to 3858.8)2678.0 (1924.1 to 3727.3)21.6 (18.4 to 25.4)
12-17 Years, ST2: Month 39225.1 (151.3 to 335.1)265.7 (194.0 to 363.7)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 42155.8 (102.5 to 236.8)160.6 (102.2 to 252.4)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 431611.9 (1055.2 to 2462.4)2400.5 (1558.0 to 3698.8)20.0 (20.0 to 20.0)
12-17 Years, ST2: Month 48231.7 (135.2 to 397.0)366.6 (227.4 to 591.1)20.0 (20.0 to 20.0)
12-17 Years, ST3: Month 1841.5 (28.3 to 61.0)44.8 (34.4 to 58.3)20.0 (20.0 to 20.0)
12-17 Years, ST3: Month 192052.5 (1312.9 to 3208.6)2919.2 (1746.8 to 4878.4)21.9 (19.2 to 24.9)
12-17 Years, ST3: Month 23496.9 (345.7 to 714.4)447.1 (282.0 to 708.9)20.0 (20.0 to 20.0)
12-17 Years, ST3: Month 26237.1 (164.5 to 341.7)283.1 (194.3 to 412.5)21.3 (18.7 to 24.3)
12-17 Years, ST3: Month 30143.5 (77.9 to 264.5)167.0 (103.1 to 270.7)23.0 (19.6 to 26.9)
12-17 Years, ST3: Month 312483.0 (1787.8 to 3448.5)2690.2 (1785.0 to 4054.4)22.5 (18.9 to 26.9)
12-17 Years, ST3: Month 39207.7 (142.7 to 302.3)253.9 (162.3 to 397.1)20.0 (20.0 to 20.0)
12-17 Years, ST3: Month 42142.1 (99.1 to 203.8)182.2 (115.6 to 287.1)20.0 (20.0 to 20.0)
12-17 Years, ST3: Month 431530.5 (1046.5 to 2238.4)2339.8 (1523.4 to 3593.8)21.1 (18.8 to 23.7)
12-17 Years, ST3: Month 48264.8 (156.3 to 448.6)392.2 (237.5 to 647.7)21.3 (18.6 to 24.5)
12-17 Years, ST4: Month 1838.0 (27.7 to 52.2)33.6 (26.8 to 42.0)21.0 (19.6 to 22.5)
12-17 Years, ST4: Month 191738.3 (1100.8 to 2745.2)2295.9 (1323.2 to 3983.7)22.8 (19.5 to 26.7)
12-17 Years, ST4: Month 23377.6 (255.6 to 557.9)285.3 (175.9 to 462.5)23.2 (19.5 to 27.6)
12-17 Years, ST4: Month 26169.2 (109.9 to 260.5)178.1 (114.5 to 277.0)23.4 (19.5 to 28.0)
12-17 Years, ST4: Month 30113.4 (64.3 to 200.0)112.7 (66.7 to 190.5)21.5 (18.4 to 25.1)
12-17 Years, ST4: Month 312527.9 (1857.0 to 3441.0)2274.1 (1492.7 to 3464.6)22.6 (18.9 to 26.9)
12-17 Years, ST4: Month 39166.1 (108.9 to 253.3)180.2 (109.8 to 295.7)20.0 (20.0 to 20.0)
12-17 Years, ST4: Month 42119.4 (80.9 to 176.2)121.5 (75.9 to 194.4)20.0 (20.0 to 20.0)
12-17 Years, ST4: Month 431583.8 (1088.2 to 2305.2)1895.2 (1210.3 to 2967.8)23.2 (18.5 to 29.0)
12-17 Years, ST4: Month 48227.3 (135.2 to 382.1)269.4 (164.3 to 442.0)20.0 (20.0 to 20.0)
12-17 Years, ST5: Month 1835.8 (25.5 to 50.1)29.5 (23.9 to 36.4)20.6 (19.4 to 21.9)
12-17 Years, ST5: Month 191549.7 (988.0 to 2430.9)2065.7 (1230.6 to 3467.7)21.2 (18.8 to 23.7)
12-17 Years, ST5: Month 23334.5 (226.5 to 493.9)244.7 (153.9 to 389.0)21.3 (18.7 to 24.2)
12-17 Years, ST5: Month 26145.4 (89.0 to 237.5)160.9 (107.5 to 240.6)21.2 (18.8 to 23.9)
12-17 Years, ST5: Month 30100.5 (53.8 to 187.6)106.8 (63.4 to 179.8)20.0 (20.0 to 20.0)
12-17 Years, ST5: Month 312084.9 (1527.0 to 2846.7)2062.9 (1375.2 to 3094.5)23.0 (18.8 to 28.3)
12-17 Years, ST5: Month 39160.1 (108.7 to 236.0)181.6 (124.5 to 264.8)20.0 (20.0 to 20.0)
12-17 Years, ST5: Month 42114.4 (77.0 to 169.8)106.1 (66.1 to 170.2)20.0 (20.0 to 20.0)
12-17 Years, ST5: Month 431285.8 (891.4 to 1854.6)1802.3 (1124.4 to 2889.0)21.5 (18.4 to 25.2)
12-17 Years, ST5: Month 48191.5 (117.1 to 313.2)228.7 (130.2 to 401.9)21.5 (18.5 to 25.0)
12-17 Years, ST6: Month 1837.5 (26.8 to 52.3)31.9 (25.2 to 40.5)22.3 (20.1 to 24.9)
12-17 Years, ST6: Month 191588.3 (1008.8 to 2500.9)1975.8 (1187.5 to 3287.4)24.4 (20.0 to 29.8)
12-17 Years, ST6: Month 23336.9 (215.1 to 527.7)237.4 (148.0 to 380.7)25.8 (20.1 to 33.1)
12-17 Years, ST6: Month 26176.2 (113.7 to 273.2)150.7 (97.9 to 232.0)22.6 (18.9 to 27.0)
12-17 Years, ST6: Month 30110.6 (60.2 to 203.2)97.2 (55.3 to 170.6)27.7 (20.9 to 36.8)
12-17 Years, ST6: Month 312242.3 (1627.7 to 3089.0)1987.0 (1371.5 to 2878.8)25.1 (19.3 to 32.6)
12-17 Years, ST6: Month 39174.9 (111.7 to 273.8)161.4 (108.0 to 241.4)21.7 (18.2 to 25.9)
12-17 Years, ST6: Month 42131.2 (87.4 to 197.2)106.1 (66.3 to 169.7)20.0 (20.0 to 20.0)
12-17 Years, ST6: Month 431318.7 (907.0 to 1917.3)1613.1 (1014.0 to 2566.2)23.3 (18.6 to 29.2)
12-17 Years, ST6: Month 48209.1 (125.3 to 349.0)235.2 (141.3 to 391.5)23.8 (18.5 to 30.5)
18-65 Years, ST1: Month 1824.6 (21.2 to 28.4)21.6 (20.2 to 23.2)21.6 (19.9 to 23.4)
18-65 Years, ST1: Month 19768.3 (565.5 to 1043.9)499.6 (356.4 to 700.4)21.3 (19.7 to 23.1)
18-65 Years, ST1: Month 23130.8 (95.7 to 178.8)97.8 (71.2 to 134.1)22.1 (19.9 to 24.5)
18-65 Years, ST1: Month 2672.9 (55.5 to 95.8)56.4 (42.6 to 74.8)22.8 (20.5 to 25.2)
18-65 Years, ST1: Month 3041.1 (33.0 to 51.3)41.3 (31.8 to 53.6)20.0 (20.0 to 20.0)
18-65 Years, ST1: Month 31818.5 (635.6 to 1054.0)606.0 (456.3 to 804.7)20.0 (20.0 to 20.0)
18-65 Years, ST1: Month 3979.9 (63.6 to 100.4)59.9 (44.3 to 80.8)20.7 (19.7 to 21.7)
18-65 Years, ST1: Month 4262.7 (50.4 to 77.9)54.7 (40.6 to 73.6)20.0 (20.0 to 20.0)
18-65 Years, ST1: Month 43791.7 (651.3 to 962.3)589.1 (450.7 to 770.0)22.0 (18.2 to 26.5)
18-65 Years, ST1: Month 48169.2 (126.6 to 226.1)138.4 (103.5 to 185.2)20.0 (20.0 to 20.0)
18-65 Years, ST2: Month 1829.5 (25.6 to 34.0)23.5 (21.4 to 25.9)20.6 (19.7 to 21.6)
18-65 Years, ST2: Month 191441.7 (1128.9 to 1841.1)1144.1 (856.8 to 1527.8)20.9 (19.6 to 22.2)
18-65 Years, ST2: Month 23277.1 (219.6 to 349.7)219.3 (166.8 to 288.4)21.6 (19.7 to 23.6)
18-65 Years, ST2: Month 26134.3 (105.3 to 171.3)101.1 (75.9 to 134.6)22.2 (20.2 to 24.4)
18-65 Years, ST2: Month 3072.7 (56.5 to 93.5)70.3 (53.4 to 92.4)20.0 (20.0 to 20.0)
18-65 Years, ST2: Month 311322.1 (1109.9 to 1575.0)1028.1 (818.4 to 1291.5)20.0 (20.0 to 20.0)
18-65 Years, ST2: Month 39143.2 (114.4 to 179.2)100.0 (72.9 to 137.0)20.3 (19.7 to 20.9)
18-65 Years, ST2: Month 42111.6 (88.3 to 141.0)88.8 (66.6 to 118.4)20.0 (20.0 to 20.0)
18-65 Years, ST2: Month 431331.8 (1146.3 to 1547.4)975.7 (759.7 to 1253.2)22.0 (18.2 to 26.7)
18-65 Years, ST2: Month 48297.4 (231.2 to 382.5)234.3 (188.6 to 291.0)20.0 (20.0 to 20.0)
18-65 Years, ST3: Month 1827.0 (23.5 to 31.1)24.2 (22.0 to 26.6)20.0 (20.0 to 20.0)
18-65 Years, ST3: Month 191237.2 (963.1 to 1589.4)948.9 (710.6 to 1267.1)20.0 (20.0 to 20.0)
18-65 Years, ST3: Month 23237.3 (178.4 to 315.6)200.7 (148.8 to 270.7)21.7 (19.5 to 24.2)
18-65 Years, ST3: Month 26124.6 (97.2 to 159.6)101.3 (75.5 to 135.9)22.1 (20.1 to 24.3)
18-65 Years, ST3: Month 3066.8 (51.9 to 86.0)72.6 (54.9 to 96.1)20.8 (19.6 to 22.1)
18-65 Years, ST3: Month 311157.5 (956.5 to 1400.7)912.8 (702.6 to 1186.0)20.6 (19.5 to 21.7)
18-65 Years, ST3: Month 39133.1 (106.1 to 166.9)97.6 (71.3 to 133.5)20.7 (19.3 to 22.3)
18-65 Years, ST3: Month 4296.0 (75.9 to 121.4)88.9 (66.6 to 118.5)20.6 (19.4 to 22.0)
18-65 Years, ST3: Month 431104.0 (925.1 to 1317.4)820.3 (627.5 to 1072.4)22.0 (18.2 to 26.6)
18-65 Years, ST3: Month 48279.3 (212.3 to 367.3)232.1 (178.2 to 302.3)20.0 (20.0 to 20.0)
18-65 Years, ST4: Month 1826.8 (23.4 to 30.8)22.3 (20.5 to 24.3)21.5 (19.9 to 23.3)
18-65 Years, ST4: Month 19994.2 (762.2 to 1296.8)668.9 (487.6 to 917.5)21.2 (19.6 to 23.0)
18-65 Years, ST4: Month 23159.1 (118.9 to 212.9)121.5 (90.0 to 164.1)22.5 (19.9 to 25.5)
18-65 Years, ST4: Month 2695.6 (75.3 to 121.4)67.8 (51.0 to 90.1)23.6 (20.9 to 26.6)
18-65 Years, ST4: Month 3055.5 (44.4 to 69.3)47.1 (36.4 to 60.9)21.5 (19.4 to 23.9)
18-65 Years, ST4: Month 311058.7 (866.2 to 1294.1)747.9 (570.9 to 979.8)22.3 (19.7 to 25.4)
18-65 Years, ST4: Month 39106.0 (84.3 to 133.1)79.3 (59.3 to 106.0)21.6 (19.4 to 24.1)
18-65 Years, ST4: Month 4282.3 (65.6 to 103.4)72.3 (53.6 to 97.5)22.0 (19.6 to 24.7)
18-65 Years, ST4: Month 431051.5 (882.2 to 1253.2)754.6 (585.5 to 972.5)23.2 (18.9 to 28.4)
18-65 Years, ST4: Month 48223.0 (169.9 to 292.7)176.3 (139.2 to 223.3)21.0 (19.0 to 23.1)
18-65 Years, ST5: Month 1824.2 (21.4 to 27.4)21.7 (20.3 to 23.1)20.2 (19.8 to 20.5)
18-65 Years, ST5: Month 19930.5 (702.6 to 1232.3)637.0 (460.8 to 880.6)20.0 (20.0 to 20.0)
18-65 Years, ST5: Month 23164.9 (126.3 to 215.4)105.8 (76.3 to 146.8)21.3 (19.5 to 23.3)
18-65 Years, ST5: Month 2695.1 (75.0 to 120.6)62.6 (46.9 to 83.6)22.4 (20.3 to 24.7)
18-65 Years, ST5: Month 3047.7 (37.4 to 60.8)48.3 (37.1 to 63.0)20.5 (19.5 to 21.6)
18-65 Years, ST5: Month 31974.1 (797.9 to 1189.3)696.3 (546.3 to 887.5)20.6 (19.4 to 22.0)
18-65 Years, ST5: Month 39102.2 (82.5 to 126.7)70.9 (53.0 to 95.0)20.9 (19.6 to 22.3)
18-65 Years, ST5: Month 4272.3 (57.6 to 90.9)69.9 (53.3 to 91.8)20.5 (19.5 to 21.4)
18-65 Years, ST5: Month 43937.6 (789.8 to 1113.1)688.1 (540.9 to 875.3)22.0 (18.2 to 26.7)
18-65 Years, ST5: Month 48194.9 (146.5 to 259.3)142.0 (104.3 to 193.4)20.0 (20.0 to 20.0)
18-65 Years, ST6: Month 1826.5 (23.0 to 30.6)21.8 (20.3 to 23.3)21.1 (20.0 to 22.3)
18-65 Years, ST6: Month 19913.7 (700.2 to 1192.2)621.8 (447.7 to 863.8)21.3 (20.0 to 22.7)
18-65 Years, ST6: Month 23166.9 (126.6 to 220.0)123.7 (92.5 to 165.4)21.5 (19.6 to 23.6)
18-65 Years, ST6: Month 2699.8 (77.7 to 128.2)65.9 (49.9 to 87.2)23.2 (20.9 to 25.7)
18-65 Years, ST6: Month 3052.0 (40.3 to 67.0)50.2 (38.9 to 64.7)21.0 (19.6 to 22.4)
18-65 Years, ST6: Month 31962.8 (791.1 to 1171.8)679.3 (531.4 to 868.5)21.1 (19.5 to 22.9)
18-65 Years, ST6: Month 39100.9 (79.2 to 128.6)71.2 (52.9 to 95.9)21.6 (19.6 to 23.7)
18-65 Years, ST6: Month 4280.2 (62.8 to 102.4)68.3 (51.1 to 91.4)20.8 (19.3 to 22.4)
18-65 Years, ST6: Month 43939.6 (785.9 to 1123.3)676.9 (526.3 to 870.5)22.7 (18.7 to 27.5)
18-65 Years, ST6: Month 48210.1 (155.5 to 283.8)161.2 (124.7 to 208.5)20.4 (19.6 to 21.3)
SecondarySCR Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48

Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.

Time frame:
Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Reported as:
Number · Percentage of participants
SCR Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Percentage of participantsGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
5-11 Years, ST1: Month 1820.0 (10.0 to 35.9)8.8 (3.0 to 23.0)0.0 (0.0 to 9.4)
5-11 Years, ST1: Month 1996.3 (81.7 to 99.3)90.0 (69.9 to 97.2)0.0 (0.0 to 11.4)
5-11 Years, ST1: Month 2389.3 (72.8 to 96.3)81.8 (61.5 to 92.7)0.0 (0.0 to 12.1)
5-11 Years, ST1: Month 2687.0 (67.9 to 95.5)70.6 (46.9 to 86.7)0.0 (0.0 to 13.8)
5-11 Years, ST1: Month 3076.9 (57.9 to 89.0)52.4 (32.4 to 71.7)0.0 (0.0 to 13.8)
5-11 Years, ST1: Month 3196.3 (81.7 to 99.3)90.9 (72.2 to 97.5)4.3 (0.8 to 21.0)
5-11 Years, ST1: Month 3984.0 (65.3 to 93.6)90.9 (62.3 to 98.4)5.0 (0.9 to 23.6)
5-11 Years, ST1: Month 4285.7 (65.4 to 95.0)92.3 (66.7 to 98.6)11.8 (3.3 to 34.3)
5-11 Years, ST1: Month 43100 (87.1 to 100)100 (81.6 to 100)0.0 (0.0 to 17.6)
5-11 Years, ST1: Month 48100 (83.9 to 100)92.9 (68.5 to 98.7)0.0 (0.0 to 20.4)
5-11 Years, ST2: Month 1857.1 (40.9 to 72.0)50.0 (34.1 to 65.9)0.0 (0.0 to 9.4)
5-11 Years, ST2: Month 1996.3 (81.7 to 99.3)90.0 (69.9 to 97.2)0.0 (0.0 to 11.4)
5-11 Years, ST2: Month 2396.4 (82.3 to 99.4)90.9 (72.2 to 97.5)0.0 (0.0 to 12.1)
5-11 Years, ST2: Month 26100 (85.7 to 100)82.4 (59.0 to 93.8)0.0 (0.0 to 13.8)
5-11 Years, ST2: Month 30100 (87.1 to 100)76.2 (54.9 to 89.4)0.0 (0.0 to 13.8)
5-11 Years, ST2: Month 3196.3 (81.7 to 99.3)95.5 (78.2 to 99.2)4.3 (0.8 to 21.0)
5-11 Years, ST2: Month 3992.0 (75.0 to 97.8)100 (74.1 to 100)5.0 (0.9 to 23.6)
5-11 Years, ST2: Month 4290.5 (71.1 to 97.3)100 (77.2 to 100)5.9 (1.0 to 27.0)
5-11 Years, ST2: Month 43100 (87.1 to 100)100 (81.6 to 100)0.0 (0.0 to 17.6)
5-11 Years, ST2: Month 48100 (83.9 to 100)100 (78.5 to 100)0.0 (0.0 to 20.4)
5-11 Years, ST3: Month 1854.3 (38.2 to 69.5)70.6 (53.8 to 83.2)2.7 (0.5 to 13.8)
5-11 Years, ST3: Month 1996.3 (81.7 to 99.3)90.0 (69.9 to 97.2)6.7 (1.8 to 21.3)
5-11 Years, ST3: Month 2396.4 (82.3 to 99.4)95.5 (78.2 to 99.2)0.0 (0.0 to 12.1)
5-11 Years, ST3: Month 2695.7 (79.0 to 99.2)94.1 (73.0 to 99.0)0.0 (0.0 to 13.8)
5-11 Years, ST3: Month 3084.6 (66.5 to 93.8)85.7 (65.4 to 95.0)4.2 (0.7 to 20.2)
5-11 Years, ST3: Month 3196.3 (81.7 to 99.3)95.5 (78.2 to 99.2)4.3 (0.8 to 21.0)
5-11 Years, ST3: Month 3988.0 (70.0 to 95.8)100 (74.1 to 100)5.0 (0.9 to 23.6)
5-11 Years, ST3: Month 4295.2 (77.3 to 99.2)100 (77.2 to 100)5.9 (1.0 to 27.0)
5-11 Years, ST3: Month 43100 (87.1 to 100)100 (81.6 to 100)5.6 (1.0 to 25.8)
5-11 Years, ST3: Month 48100 (83.9 to 100)100 (78.5 to 100)6.7 (1.2 to 29.8)
5-11 Years, ST4: Month 1848.6 (33.0 to 64.4)29.4 (16.8 to 46.2)0.0 (0.0 to 9.4)
5-11 Years, ST4: Month 1996.3 (81.7 to 99.3)90.0 (69.9 to 97.2)3.3 (0.6 to 16.7)
5-11 Years, ST4: Month 2396.4 (82.3 to 99.4)90.9 (72.2 to 97.5)0.0 (0.0 to 12.1)
5-11 Years, ST4: Month 2695.7 (79.0 to 99.2)76.5 (52.7 to 90.4)0.0 (0.0 to 13.8)
5-11 Years, ST4: Month 3084.6 (66.5 to 93.8)71.4 (50.0 to 86.2)0.0 (0.0 to 13.8)
5-11 Years, ST4: Month 3196.3 (81.7 to 99.3)90.9 (72.2 to 97.5)4.3 (0.8 to 21.0)
5-11 Years, ST4: Month 3984.0 (65.3 to 93.6)100 (74.1 to 100)5.0 (0.9 to 23.6)
5-11 Years, ST4: Month 4295.2 (77.3 to 99.2)84.6 (57.8 to 95.7)11.8 (3.3 to 34.3)
5-11 Years, ST4: Month 43100 (87.1 to 100)100 (81.6 to 100)0.0 (0.0 to 17.6)
5-11 Years, ST4: Month 48100 (83.9 to 100)100 (78.5 to 100)0.0 (0.0 to 20.4)
5-11 Years, ST5: Month 1842.9 (28.0 to 59.1)29.4 (16.8 to 46.2)0.0 (0.0 to 9.4)
5-11 Years, ST5: Month 1996.3 (81.7 to 99.3)90.0 (69.9 to 97.2)0.0 (0.0 to 11.4)
5-11 Years, ST5: Month 2392.9 (77.4 to 98.0)81.8 (61.5 to 92.7)0.0 (0.0 to 12.1)
5-11 Years, ST5: Month 26100 (85.7 to 100)76.5 (52.7 to 90.4)0.0 (0.0 to 13.8)
5-11 Years, ST5: Month 3088.5 (71.0 to 96.0)76.2 (54.9 to 89.4)0.0 (0.0 to 13.8)
5-11 Years, ST5: Month 3196.3 (81.7 to 99.3)95.5 (78.2 to 99.2)4.3 (0.8 to 21.0)
5-11 Years, ST5: Month 3984.0 (65.3 to 93.6)100 (74.1 to 100)5.0 (0.9 to 23.6)
5-11 Years, ST5: Month 4295.2 (77.3 to 99.2)92.3 (66.7 to 98.6)0.0 (0.0 to 18.4)
5-11 Years, ST5: Month 43100 (87.1 to 100)100 (81.6 to 100)0.0 (0.0 to 17.6)
5-11 Years, ST5: Month 48100 (83.9 to 100)92.9 (68.5 to 98.7)0.0 (0.0 to 20.4)
5-11 Years, ST6: Month 1827.8 (15.8 to 44.0)32.4 (19.1 to 49.2)0.0 (0.0 to 9.4)
5-11 Years, ST6: Month 1992.9 (77.4 to 98.0)90.0 (69.9 to 97.2)6.7 (1.8 to 21.3)
5-11 Years, ST6: Month 2392.9 (77.4 to 98.0)81.8 (61.5 to 92.7)0.0 (0.0 to 12.1)
5-11 Years, ST6: Month 2695.7 (79.0 to 99.2)76.5 (52.7 to 90.4)0.0 (0.0 to 13.8)
5-11 Years, ST6: Month 3076.9 (57.9 to 89.0)81.0 (60.0 to 92.3)0.0 (0.0 to 13.8)
5-11 Years, ST6: Month 3196.3 (81.7 to 99.3)90.9 (72.2 to 97.5)4.3 (0.8 to 21.0)
5-11 Years, ST6: Month 3992.0 (75.0 to 97.8)100 (74.1 to 100)5.0 (0.9 to 23.6)
5-11 Years, ST6: Month 4290.5 (71.1 to 97.3)76.9 (49.7 to 91.8)5.9 (1.0 to 27.0)
5-11 Years, ST6: Month 43100 (87.1 to 100)100 (81.6 to 100)5.6 (1.0 to 25.8)
5-11 Years, ST6: Month 48100 (83.9 to 100)92.9 (68.5 to 98.7)0.0 (0.0 to 20.4)
12-17 Years, ST1: Month 1827.8 (15.8 to 44.0)16.2 (7.7 to 31.1)0.0 (0.0 to 10.2)
12-17 Years, ST1: Month 1996.3 (81.7 to 99.3)96.2 (81.1 to 99.3)0.0 (0.0 to 12.9)
12-17 Years, ST1: Month 23100 (86.7 to 100)92.6 (76.6 to 97.9)0.0 (0.0 to 15.5)
12-17 Years, ST1: Month 2683.3 (64.1 to 93.3)68.0 (48.4 to 82.8)0.0 (0.0 to 15.5)
12-17 Years, ST1: Month 3071.4 (50.0 to 86.2)66.7 (45.4 to 82.8)0.0 (0.0 to 16.8)
12-17 Years, ST1: Month 31100 (83.9 to 100)100 (84.5 to 100)0.0 (0.0 to 15.5)
12-17 Years, ST1: Month 3995.2 (77.3 to 99.2)87.0 (67.9 to 95.5)0.0 (0.0 to 22.8)
12-17 Years, ST1: Month 4287.0 (67.9 to 95.5)75.0 (53.1 to 88.8)0.0 (0.0 to 20.4)
12-17 Years, ST1: Month 43100 (85.7 to 100)100 (84.5 to 100)6.3 (1.1 to 28.3)
12-17 Years, ST1: Month 4890.0 (69.9 to 97.2)94.7 (75.4 to 99.1)0.0 (0.0 to 18.4)
12-17 Years, ST2: Month 1841.7 (27.1 to 57.8)48.6 (33.4 to 64.1)0.0 (0.0 to 10.2)
12-17 Years, ST2: Month 1996.3 (81.7 to 99.3)96.2 (81.1 to 99.3)0.0 (0.0 to 12.9)
12-17 Years, ST2: Month 23100 (86.7 to 100)96.3 (81.7 to 99.3)0.0 (0.0 to 15.5)
12-17 Years, ST2: Month 26100 (86.2 to 100)100 (86.7 to 100)4.8 (0.8 to 22.7)
12-17 Years, ST2: Month 3081.0 (60.0 to 92.3)95.2 (77.3 to 99.2)5.3 (0.9 to 24.6)
12-17 Years, ST2: Month 31100 (83.9 to 100)100 (84.5 to 100)4.8 (0.8 to 22.7)
12-17 Years, ST2: Month 39100 (84.5 to 100)100 (85.7 to 100)0.0 (0.0 to 22.8)
12-17 Years, ST2: Month 4291.3 (73.2 to 97.6)90.0 (69.9 to 97.2)0.0 (0.0 to 20.4)
12-17 Years, ST2: Month 43100 (85.7 to 100)100 (84.5 to 100)0.0 (0.0 to 19.4)
12-17 Years, ST2: Month 4890.0 (69.9 to 97.2)94.7 (75.4 to 99.1)0.0 (0.0 to 18.4)
12-17 Years, ST3: Month 1838.9 (24.8 to 55.1)54.1 (38.4 to 69.0)0.0 (0.0 to 10.2)
12-17 Years, ST3: Month 1996.3 (81.7 to 99.3)96.2 (81.1 to 99.3)3.8 (0.7 to 18.9)
12-17 Years, ST3: Month 23100 (86.7 to 100)96.3 (81.7 to 99.3)0.0 (0.0 to 15.5)
12-17 Years, ST3: Month 26100 (86.2 to 100)100 (86.7 to 100)4.8 (0.8 to 22.7)
12-17 Years, ST3: Month 3085.7 (65.4 to 95.0)95.2 (77.3 to 99.2)15.8 (5.5 to 37.6)
12-17 Years, ST3: Month 31100 (83.9 to 100)100 (84.5 to 100)9.5 (2.7 to 28.9)
12-17 Years, ST3: Month 39100 (84.5 to 100)95.7 (79.0 to 99.2)0.0 (0.0 to 22.8)
12-17 Years, ST3: Month 4295.7 (79.0 to 99.2)95.0 (76.4 to 99.1)0.0 (0.0 to 20.4)
12-17 Years, ST3: Month 43100 (85.7 to 100)100 (84.5 to 100)6.3 (1.1 to 28.3)
12-17 Years, ST3: Month 4890.0 (69.9 to 97.2)94.7 (75.4 to 99.1)5.9 (1.0 to 27.0)
12-17 Years, ST4: Month 1844.4 (29.5 to 60.4)29.7 (17.5 to 45.8)0.0 (0.0 to 10.2)
12-17 Years, ST4: Month 1996.3 (81.7 to 99.3)96.2 (81.1 to 99.3)3.8 (0.7 to 18.9)
12-17 Years, ST4: Month 23100 (86.7 to 100)96.3 (81.7 to 99.3)4.8 (0.8 to 22.7)
12-17 Years, ST4: Month 2691.7 (74.2 to 97.7)92.0 (75.0 to 97.8)4.8 (0.8 to 22.7)
12-17 Years, ST4: Month 3081.0 (60.0 to 92.3)71.4 (50.0 to 86.2)0.0 (0.0 to 16.8)
12-17 Years, ST4: Month 31100 (83.9 to 100)100 (84.5 to 100)0.0 (0.0 to 15.5)
12-17 Years, ST4: Month 3990.5 (71.1 to 97.3)87.0 (67.9 to 95.5)0.0 (0.0 to 22.8)
12-17 Years, ST4: Month 4287.0 (67.9 to 95.5)80.0 (58.4 to 91.9)0.0 (0.0 to 20.4)
12-17 Years, ST4: Month 43100 (85.7 to 100)100 (84.5 to 100)12.5 (3.5 to 36.0)
12-17 Years, ST4: Month 4890.0 (69.9 to 97.2)94.7 (75.4 to 99.1)0.0 (0.0 to 18.4)
12-17 Years, ST5: Month 1833.3 (20.2 to 49.7)24.3 (13.4 to 40.1)2.9 (0.5 to 14.9)
12-17 Years, ST5: Month 1996.3 (81.7 to 99.3)96.2 (81.1 to 99.3)3.8 (0.7 to 18.9)
12-17 Years, ST5: Month 23100 (86.7 to 100)92.6 (76.6 to 97.9)4.8 (0.8 to 22.7)
12-17 Years, ST5: Month 2683.3 (64.1 to 93.3)92.0 (75.0 to 97.8)4.8 (0.8 to 22.7)
12-17 Years, ST5: Month 3066.7 (45.4 to 82.8)76.2 (54.9 to 89.4)0.0 (0.0 to 16.8)
12-17 Years, ST5: Month 31100 (83.9 to 100)100 (84.5 to 100)9.5 (2.7 to 28.9)
12-17 Years, ST5: Month 3995.2 (77.3 to 99.2)100 (85.7 to 100)0.0 (0.0 to 22.8)
12-17 Years, ST5: Month 4287.0 (67.9 to 95.5)80.0 (58.4 to 91.9)0.0 (0.0 to 20.4)
12-17 Years, ST5: Month 43100 (85.7 to 100)100 (84.5 to 100)6.3 (1.1 to 28.3)
12-17 Years, ST5: Month 4890.0 (69.9 to 97.2)89.5 (68.6 to 97.1)5.9 (1.0 to 27.0)
12-17 Years, ST6: Month 1833.3 (20.2 to 49.7)21.6 (11.4 to 37.2)2.9 (0.5 to 14.9)
12-17 Years, ST6: Month 1996.3 (81.7 to 99.3)96.2 (81.1 to 99.3)0.0 (0.0 to 12.9)
12-17 Years, ST6: Month 2396.0 (80.5 to 99.3)88.9 (71.9 to 96.1)0.0 (0.0 to 15.5)
12-17 Years, ST6: Month 2695.8 (79.8 to 99.3)80.0 (60.9 to 91.1)0.0 (0.0 to 15.5)
12-17 Years, ST6: Month 3066.7 (45.4 to 82.8)61.9 (40.9 to 79.2)10.5 (2.9 to 31.4)
12-17 Years, ST6: Month 31100 (83.9 to 100)100 (84.5 to 100)0.0 (0.0 to 15.5)
12-17 Years, ST6: Month 3995.2 (77.3 to 99.2)91.3 (73.2 to 97.6)0.0 (0.0 to 22.8)
12-17 Years, ST6: Month 4287.0 (67.9 to 95.5)80.0 (58.4 to 91.9)0.0 (0.0 to 20.4)
12-17 Years, ST6: Month 43100 (85.7 to 100)100 (84.5 to 100)0.0 (0.0 to 19.4)
12-17 Years, ST6: Month 4885.0 (64.0 to 94.8)89.5 (68.6 to 97.1)0.0 (0.0 to 18.4)
18-65 Years, ST1: Month 1810.5 (5.6 to 18.7)6.8 (3.0 to 15.1)0.0 (0.0 to 4.3)
18-65 Years, ST1: Month 1997.2 (90.4 to 99.2)95.4 (87.3 to 98.4)0.0 (0.0 to 5.4)
18-65 Years, ST1: Month 2382.3 (71.0 to 89.8)75.0 (62.8 to 84.2)2.9 (0.8 to 10.0)
18-65 Years, ST1: Month 2668.3 (56.0 to 78.4)57.4 (44.9 to 69.0)6.0 (2.3 to 14.4)
18-65 Years, ST1: Month 3045.0 (33.1 to 57.5)41.8 (29.7 to 55.0)0.0 (0.0 to 6.6)
18-65 Years, ST1: Month 3197.0 (89.6 to 99.2)100 (93.5 to 100)0.0 (0.0 to 6.8)
18-65 Years, ST1: Month 3973.8 (61.6 to 83.2)59.2 (45.2 to 71.8)1.9 (0.3 to 9.9)
18-65 Years, ST1: Month 4270.5 (58.1 to 80.4)57.1 (43.3 to 70.0)0.0 (0.0 to 6.8)
18-65 Years, ST1: Month 43100 (94.3 to 100)98.1 (90.1 to 99.7)1.9 (0.3 to 9.8)
18-65 Years, ST1: Month 4890.4 (79.4 to 95.8)93.5 (82.5 to 97.8)0.0 (0.0 to 8.2)
18-65 Years, ST2: Month 1825.6 (17.5 to 35.7)13.7 (7.6 to 23.4)0.0 (0.0 to 4.3)
18-65 Years, ST2: Month 1998.6 (92.5 to 99.8)98.5 (91.8 to 99.7)0.0 (0.0 to 5.4)
18-65 Years, ST2: Month 2395.2 (86.7 to 98.3)91.7 (81.9 to 96.4)1.4 (0.3 to 7.8)
18-65 Years, ST2: Month 2685.7 (75.0 to 92.3)73.8 (61.6 to 83.2)6.0 (2.3 to 14.4)
18-65 Years, ST2: Month 3068.3 (55.8 to 78.7)65.5 (52.3 to 76.6)0.0 (0.0 to 6.6)
18-65 Years, ST2: Month 31100 (94.5 to 100)100 (93.5 to 100)0.0 (0.0 to 6.8)
18-65 Years, ST2: Month 3986.9 (76.2 to 93.2)73.5 (59.7 to 83.8)1.9 (0.3 to 9.9)
18-65 Years, ST2: Month 4282.0 (70.5 to 89.6)73.5 (59.7 to 83.8)0.0 (0.0 to 6.8)
18-65 Years, ST2: Month 43100 (94.3 to 100)98.1 (90.1 to 99.7)1.9 (0.3 to 9.8)
18-65 Years, ST2: Month 4894.2 (84.4 to 98.0)97.8 (88.7 to 99.6)0.0 (0.0 to 8.2)
18-65 Years, ST3: Month 1818.6 (11.8 to 28.1)19.2 (11.8 to 29.7)0.0 (0.0 to 4.3)
18-65 Years, ST3: Month 1998.6 (92.5 to 99.8)98.5 (91.8 to 99.7)0.0 (0.0 to 5.4)
18-65 Years, ST3: Month 2388.7 (78.5 to 94.4)88.3 (77.8 to 94.2)2.9 (0.8 to 10.0)
18-65 Years, ST3: Month 2684.1 (73.2 to 91.1)77.0 (65.1 to 85.8)7.5 (3.2 to 16.3)
18-65 Years, ST3: Month 3066.7 (54.1 to 77.3)69.1 (56.0 to 79.7)3.7 (1.0 to 12.5)
18-65 Years, ST3: Month 31100 (94.5 to 100)100 (93.5 to 100)1.9 (0.3 to 9.9)
18-65 Years, ST3: Month 3988.5 (78.2 to 94.3)75.5 (61.9 to 85.4)1.9 (0.3 to 9.9)
18-65 Years, ST3: Month 4283.6 (72.4 to 90.8)79.6 (66.4 to 88.5)1.9 (0.3 to 9.9)
18-65 Years, ST3: Month 43100 (94.3 to 100)98.1 (90.1 to 99.7)1.9 (0.3 to 9.8)
18-65 Years, ST3: Month 4896.2 (87.0 to 98.9)95.7 (85.5 to 98.8)0.0 (0.0 to 8.2)
18-65 Years, ST4: Month 1818.6 (11.8 to 28.1)9.6 (4.7 to 18.5)2.4 (0.6 to 8.2)
18-65 Years, ST4: Month 1998.6 (92.5 to 99.8)95.4 (87.3 to 98.4)3.0 (0.8 to 10.2)
18-65 Years, ST4: Month 2385.5 (74.7 to 92.2)83.3 (72.0 to 90.7)2.9 (0.8 to 10.0)
18-65 Years, ST4: Month 2681.0 (69.6 to 88.8)63.9 (51.4 to 74.8)10.4 (5.2 to 20.0)
18-65 Years, ST4: Month 3065.0 (52.4 to 75.8)52.7 (39.8 to 65.3)1.9 (0.3 to 9.8)
18-65 Years, ST4: Month 31100 (94.5 to 100)100 (93.5 to 100)3.8 (1.0 to 12.8)
18-65 Years, ST4: Month 3983.6 (72.4 to 90.8)73.5 (59.7 to 83.8)1.9 (0.3 to 9.9)
18-65 Years, ST4: Month 4277.0 (65.1 to 85.8)69.4 (55.5 to 80.5)3.8 (1.0 to 12.8)
18-65 Years, ST4: Month 43100 (94.3 to 100)98.1 (90.1 to 99.7)3.7 (1.0 to 12.5)
18-65 Years, ST4: Month 4894.2 (84.4 to 98.0)100 (92.3 to 100)0.0 (0.0 to 8.2)
18-65 Years, ST5: Month 1811.6 (6.4 to 20.1)8.2 (3.8 to 16.8)1.2 (0.2 to 6.4)
18-65 Years, ST5: Month 1997.2 (90.4 to 99.2)95.4 (87.3 to 98.4)0.0 (0.0 to 5.4)
18-65 Years, ST5: Month 2387.1 (76.6 to 93.3)70.0 (57.5 to 80.1)2.9 (0.8 to 10.0)
18-65 Years, ST5: Month 2681.0 (69.6 to 88.8)55.7 (43.3 to 67.5)7.5 (3.2 to 16.3)
18-65 Years, ST5: Month 3048.3 (36.2 to 60.7)49.1 (36.4 to 61.9)1.9 (0.3 to 9.8)
18-65 Years, ST5: Month 31100 (94.5 to 100)100 (93.5 to 100)1.9 (0.3 to 9.9)
18-65 Years, ST5: Month 3983.6 (72.4 to 90.8)67.3 (53.4 to 78.8)3.8 (1.0 to 12.8)
18-65 Years, ST5: Month 4272.1 (59.8 to 81.8)75.5 (61.9 to 85.4)1.9 (0.3 to 9.9)
18-65 Years, ST5: Month 43100 (94.3 to 100)98.1 (90.1 to 99.7)1.9 (0.3 to 9.8)
18-65 Years, ST5: Month 4890.4 (79.4 to 95.8)84.8 (71.8 to 92.4)0.0 (0.0 to 8.2)
18-65 Years, ST6: Month 1815.1 (9.1 to 24.2)6.8 (3.0 to 15.1)3.5 (1.2 to 9.9)
18-65 Years, ST6: Month 1998.6 (92.5 to 99.8)95.4 (87.3 to 98.4)4.5 (1.5 to 12.4)
18-65 Years, ST6: Month 2387.1 (76.6 to 93.3)81.7 (70.1 to 89.4)4.3 (1.5 to 12.0)
18-65 Years, ST6: Month 2679.4 (67.8 to 87.5)57.4 (44.9 to 69.0)11.9 (6.2 to 21.8)
18-65 Years, ST6: Month 3050.0 (37.7 to 62.3)50.9 (38.1 to 63.6)3.7 (1.0 to 12.5)
18-65 Years, ST6: Month 31100 (94.5 to 100)100 (93.5 to 100)3.8 (1.0 to 12.8)
18-65 Years, ST6: Month 3978.7 (66.9 to 87.1)65.3 (51.3 to 77.1)5.7 (1.9 to 15.4)
18-65 Years, ST6: Month 4272.1 (59.8 to 81.8)65.3 (51.3 to 77.1)1.9 (0.3 to 9.9)
18-65 Years, ST6: Month 43100 (94.3 to 100)98.1 (90.1 to 99.7)3.7 (1.0 to 12.5)
18-65 Years, ST6: Month 4892.3 (81.8 to 97.0)95.7 (85.5 to 98.8)2.3 (0.4 to 12.1)
SecondaryGMFR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 19, 31 and 43 During the Booster Phase

GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6), stratified by age group (5-11, 12-17 and 18-65 years) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.

Time frame:
Months 19, 31 and 43
Reported as:
Geometric mean · Fold rise
GMFR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 19, 31 and 43 During the Booster Phase
Fold riseGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: Placebo
5-11 Years, ST1: Month 1954.0 (35.4 to 82.5)58.7 (27.2 to 126.5)1.0 (1.0 to 1.0)
5-11 Years, ST1: Month 3117.4 (8.1 to 37.4)23.0 (10.3 to 51.3)1.2 (0.8 to 2.0)
5-11 Years, ST1: Month 4316.5 (11.6 to 23.3)24.3 (14.6 to 40.7)0.9 (0.7 to 1.1)
5-11 Years, ST2: Month 1963.1 (39.7 to 100.3)49.0 (20.7 to 115.7)1.0 (1.0 to 1.0)
5-11 Years, ST2: Month 3113.4 (6.7 to 27.1)18.9 (9.2 to 39.2)1.3 (0.8 to 2.0)
5-11 Years, ST2: Month 4314.3 (9.8 to 20.8)20.4 (11.6 to 35.8)0.9 (0.7 to 1.2)
5-11 Years, ST3: Month 1953.8 (33.9 to 85.4)37.4 (17.0 to 82.7)1.1 (1.0 to 1.2)
5-11 Years, ST3: Month 3114.6 (7.1 to 30.4)14.4 (6.7 to 30.9)1.2 (0.7 to 2.0)
5-11 Years, ST3: Month 4312.6 (8.6 to 18.4)20.1 (11.3 to 35.8)1.0 (0.8 to 1.3)
5-11 Years, ST4: Month 1949.8 (30.6 to 81.1)59.6 (26.6 to 133.7)1.1 (1.0 to 1.2)
5-11 Years, ST4: Month 3116.2 (7.8 to 33.7)21.0 (10.2 to 43.1)1.2 (0.8 to 2.0)
5-11 Years, ST4: Month 4313.2 (9.2 to 19.0)26.0 (15.0 to 45.3)0.9 (0.7 to 1.1)
5-11 Years, ST5: Month 1957.1 (36.2 to 90.3)54.0 (24.9 to 117.3)1.0 (1.0 to 1.0)
5-11 Years, ST5: Month 3115.3 (7.4 to 31.7)17.4 (8.6 to 35.0)1.3 (0.8 to 2.1)
5-11 Years, ST5: Month 4313.8 (10.1 to 18.9)21.5 (12.7 to 36.6)1.0 (1.0 to 1.0)
5-11 Years, ST6: Month 1949.8 (29.4 to 84.6)52.0 (24.6 to 110.0)1.1 (1.0 to 1.3)
5-11 Years, ST6: Month 3116.1 (7.8 to 33.0)16.1 (8.1 to 31.9)1.4 (0.8 to 2.2)
5-11 Years, ST6: Month 4314.9 (10.8 to 20.5)23.4 (14.1 to 39.0)1.0 (0.8 to 1.2)
12-17 Years, ST1: Month 1943.4 (25.8 to 73.0)78.4 (46.7 to 131.5)1.0 (1.0 to 1.0)
12-17 Years, ST1: Month 3125.7 (14.3 to 46.0)29.8 (18.2 to 49.0)0.9 (0.8 to 1.1)
12-17 Years, ST1: Month 4312.4 (8.0 to 19.2)18.1 (11.2 to 29.1)1.1 (0.9 to 1.3)
12-17 Years, ST2: Month 1946.2 (27.8 to 76.7)73.9 (47.0 to 116.3)1.0 (1.0 to 1.0)
12-17 Years, ST2: Month 3119.8 (11.0 to 35.5)16.8 (12.0 to 23.6)1.0 (1.0 to 1.1)
12-17 Years, ST2: Month 4310.3 (6.8 to 15.8)14.4 (8.8 to 23.4)1.0 (1.0 to 1.0)
12-17 Years, ST3: Month 1945.0 (27.3 to 74.2)70.6 (43.7 to 113.9)1.1 (1.0 to 1.2)
12-17 Years, ST3: Month 3118.5 (10.2 to 33.4)16.7 (12.6 to 22.3)1.0 (0.8 to 1.2)
12-17 Years, ST3: Month 4310.8 (7.3 to 15.9)12.8 (8.1 to 20.0)1.1 (0.9 to 1.2)
12-17 Years, ST4: Month 1942.4 (26.0 to 69.0)68.1 (41.8 to 110.9)1.1 (1.0 to 1.2)
12-17 Years, ST4: Month 3122.2 (12.7 to 38.6)22.7 (14.8 to 34.9)1.1 (0.9 to 1.2)
12-17 Years, ST4: Month 4313.3 (8.8 to 19.9)15.1 (9.3 to 24.8)1.2 (0.9 to 1.5)
12-17 Years, ST5: Month 1940.0 (24.5 to 65.3)71.8 (43.9 to 117.4)1.0 (1.0 to 1.1)
12-17 Years, ST5: Month 3121.1 (11.8 to 37.9)23.5 (15.1 to 36.5)1.2 (0.9 to 1.4)
12-17 Years, ST5: Month 4311.2 (7.4 to 17.1)16.3 (10.4 to 25.6)1.1 (0.9 to 1.3)
12-17 Years, ST6: Month 1939.1 (24.0 to 63.9)59.1 (37.0 to 94.3)1.1 (0.9 to 1.2)
12-17 Years, ST6: Month 3121.8 (12.5 to 38.0)23.9 (15.6 to 36.5)0.9 (0.8 to 1.1)
12-17 Years, ST6: Month 4310.0 (6.7 to 15.1)14.4 (8.8 to 23.6)1.1 (0.9 to 1.2)
18-65 Years, ST1: Month 1932.2 (24.1 to 42.9)23.4 (16.8 to 32.5)1.0 (1.0 to 1.0)
18-65 Years, ST1: Month 3118.5 (14.1 to 24.4)15.1 (11.6 to 19.5)1.0 (1.0 to 1.0)
18-65 Years, ST1: Month 4312.6 (10.2 to 15.4)11.1 (8.5 to 14.5)1.1 (0.9 to 1.3)
18-65 Years, ST2: Month 1948.3 (38.1 to 61.2)48.5 (36.6 to 64.3)1.0 (1.0 to 1.0)
18-65 Years, ST2: Month 3116.4 (13.1 to 20.6)14.5 (11.7 to 18.0)1.0 (1.0 to 1.0)
18-65 Years, ST2: Month 4312.1 (9.8 to 14.9)11.7 (8.6 to 15.8)1.1 (0.9 to 1.3)
18-65 Years, ST3: Month 1944.9 (34.8 to 57.9)39.5 (30.4 to 51.5)1.0 (1.0 to 1.0)
18-65 Years, ST3: Month 3117.0 (13.4 to 21.5)13.1 (10.7 to 15.9)1.0 (1.0 to 1.0)
18-65 Years, ST3: Month 4311.5 (9.6 to 13.8)9.5 (7.3 to 12.2)1.1 (0.9 to 1.3)
18-65 Years, ST4: Month 1936.0 (27.7 to 46.9)29.8 (21.8 to 40.9)1.0 (1.0 to 1.0)
18-65 Years, ST4: Month 3117.9 (14.0 to 22.8)15.7 (12.4 to 19.9)1.0 (1.0 to 1.1)
18-65 Years, ST4: Month 4313.0 (10.5 to 16.1)10.8 (8.3 to 14.0)1.1 (0.9 to 1.3)
18-65 Years, ST5: Month 1937.0 (28.0 to 48.8)29.6 (21.6 to 40.5)1.0 (1.0 to 1.0)
18-65 Years, ST5: Month 3119.2 (15.0 to 24.6)14.2 (11.4 to 17.7)1.0 (1.0 to 1.0)
18-65 Years, ST5: Month 4313.4 (10.9 to 16.4)10.3 (8.0 to 13.4)1.1 (0.9 to 1.3)
18-65 Years, ST6: Month 1932.6 (25.3 to 42.1)28.3 (20.3 to 39.5)1.0 (1.0 to 1.1)
18-65 Years, ST6: Month 3118.2 (14.3 to 23.2)12.9 (10.3 to 16.0)1.0 (1.0 to 1.1)
18-65 Years, ST6: Month 4311.8 (9.7 to 14.4)10.4 (8.0 to 13.5)1.1 (0.9 to 1.3)

Adverse events

Collected over Systematic assessment: local reactions and systemic events were assessed for up to 7 Days after each vaccination; non- systematic assessment: all-cause mortality, SAEs, AESIs were assessed up to Month 48 and other AEs (including non-SAEs) were assessed up to 28 days after each vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: VLA150/127 (0%)0/127 (0%)124/127 (97.6%)
Group 2: VLA15 + Placebo0/112 (0%)4/112 (3.6%)111/112 (99.1%)
Group 3: Placebo0/206 (0%)14/206 (6.8%)145/206 (70.4%)
Received Any VLA15 Including Wrong/Missed Vaccination1/419 (0.2%)14/419 (3.3%)403/419 (96.2%)
All Participants1/625 (0.2%)28/625 (4.5%)548/625 (87.7%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1270/1122/2060/4192/625
ConcussionInjury, poisoning and procedural complications0/1271/1120/2061/4191/625
Procedural painInjury, poisoning and procedural complications0/1271/1120/2061/4191/625
Major depressionPsychiatric disorders0/1271/1120/2061/4191/625
Lumbar radiculopathyNervous system disorders0/1271/1120/2061/4191/625
OverdoseInjury, poisoning and procedural complications0/1270/1121/2061/4192/625
Road traffic accidentInjury, poisoning and procedural complications0/1270/1121/2060/4191/625
Tibia fractureInjury, poisoning and procedural complications0/1270/1121/2060/4191/625
Wrist fractureInjury, poisoning and procedural complications0/1270/1121/2060/4191/625
Breast cancer stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1270/1121/2060/4191/625
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGroup 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboReceived Any VLA15 Including Wrong/Missed VaccinationAll Participants
Injection site painGeneral disorders122/127110/11280/206396/419476/625
MyalgiaMusculoskeletal and connective tissue disorders81/12771/11250/206238/419288/625
HeadacheNervous system disorders75/12751/11281/206196/419277/625
Injection site erythemaGeneral disorders73/12745/11223/206192/419215/625
Injection site swellingGeneral disorders70/12746/11218/206181/419199/625
Injection site indurationGeneral disorders62/12746/11216/206174/419190/625
FatigueGeneral disorders59/12753/11264/206172/419236/625
ArthralgiaMusculoskeletal and connective tissue disorders36/12712/11222/20678/419100/625
NauseaGastrointestinal disorders21/12723/11228/20671/41999/625
PyrexiaGeneral disorders11/1274/1127/20620/41927/625

Baseline characteristics

Full analysis set (FAS) included all participants enrolled who received at least one vaccination. Participants were analyzed according to the study group they had been allocated to, rather than by the actual treatment they received.

Age, Continuous
Age, Continuous(Years)Group 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboTotal
Mean28.7 ± 19.0928.9 ± 19.5629.0 ± 19.7228.9 ± 19.43
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboTotal
Female112108101321
Male96101107304
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboTotal
Hispanic or Latino23151856
Not Hispanic or Latino185194190569
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: VLA15Group 2: VLA15 + PlaceboGroup 3: PlaceboTotal
American Indian or Alaska Native1001
Asian43613
Native Hawaiian or Other Pacific Islander0000
Black or African American27172468
White172184176532
More than one race0000
Unknown or Not Reported45211
08

Study locations

19 sites
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Pediatric Associates of Conn. PC
    Waterbury, Connecticut 06708, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Foundation Pediatrics
    East Orange, New Jersey 07018, United States
  • Med Clinical Research Partners, LLC
    Irvington, New Jersey 07111, United States
  • Meridian Clinical Research LLC
    Binghamton, New York 13905, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • Advantage Clinical Trials
    The Bronx, New York 10467, United States
  • Velocity Clinical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • Liberty Family Practice
    Erie, Pennsylvania 16508, United States
  • Lockman & Lubell Pediatric Associates
    Fort Washington, Pennsylvania 19034, United States
  • Hasbro Children's Hospital
    Providence, Rhode Island 02903, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Velocity Clinical Research Providence
    Warwick, Rhode Island 02886, United States
09

References and documents

Publications

  • Wagner L, Kadlecek V, Skaroupkova J, Scharnagl N, Hochreiter R, Messier M, Jaramillo JC, Larcher-Steiner J, Hegele L, Lamberth E, Murphy T, Maguire JD, Clarkin C, Derhaschnig U, Eder-Lingelbach S. A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals. Nat Commun. 2026 Aug 4;17(1):9386. doi: 10.1038/s41467-026-75871-3. PubMed 42680745 ↗
  • Wagner L, Obersriebnig M, Hochreiter R, Kadlecek V, Larcher-Senn J, Hegele L, Maguire JD, Murphy T, Derhaschnig U, Bezay N, Jaramillo JC, Eder-Lingelbach S, Messier M. Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2026 Mar;26(3):314-328. doi: 10.1016/S1473-3099(25)00541-9. Epub 2025 Nov 7. PubMed 41213278 ↗
  • Wagner L, Obersriebnig M, Kadlecek V, Hochreiter R, Ghadge SK, Larcher-Senn J, Hegele L, Maguire JD, Derhaschnig U, Jaramillo JC, Eder-Lingelbach S, Bezay N. Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2025 Sep;25(9):986-999. doi: 10.1016/S1473-3099(25)00092-1. Epub 2025 Apr 25. PubMed 40294611 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Mar 2022, 12 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 17, 2021
StartActual
Mar 8, 2021
Primary completionActual
Mar 25, 2022
CompletionActual
Jul 2, 2025
Results first posted
Jun 7, 2023
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04801420
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Mar 8, 2021
Primary completion
Mar 25, 2022
Completion
Jul 2, 2025
Results posted
Jun 7, 2023
Last update
Sep 15, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VLA15

Start the discussion